Modeling and analysis of a within-host HIV/HTLV-I co-infection

A. M. Elaiw\textsuperscript{1,2} \& N. H. AlShamrani\textsuperscript{1,3}

Received: 23 July 2020 / Accepted: 7 November 2020 / Published online: 29 March 2021
© Sociedad Matemática Mexicana 2021

Abstract
Human immunodeficiency virus (HIV) and human T-lymphotropic virus type I (HTLV-I) are two retroviruses that attack the \( \text{CD}4^+ \) T cells and impair their functions. Both HIV and HTLV-I can be transmitted between individuals through direct contact with certain body fluids from infected individuals. Therefore, a person can be co-infected with both viruses. HIV causes acquired immunodeficiency syndrome (AIDS), while HTLV-I is the causative agent for adult T-cell leukemia (ATL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Several mathematical models have been developed in the literature to describe the within-host dynamics of HIV and HTLV-I mono-infections. However, modeling a within-host dynamics of HIV/HTLV-I co-infection has not been involved. The present paper is concerned with the formulation and investigation of a new HIV/HTLV-I co-infection model under the effect of Cytotoxic T lymphocytes (CTLs) immune response. The model describes the interaction between susceptible \( \text{CD}4^+ \) T cells, silent HIV-infected cells, active HIV-infected cells, silent HTLV-infected cells, Tax-expressing HTLV-infected cells, free HIV particles, HIV-specific CTLs and HTLV-specific CTLs. The HIV can spread by virus-to-cell transmission. On the other side, HTLV-I has two modes of transmission, (i) horizontal transmission via direct cell-to-cell contact through the virological synapse, and (ii) vertical transmission through the mitotic division of Tax-expressing HTLV-infected cells. The well-posedness of the model is established by showing that the solutions of the model are nonnegative and bounded. We define a set of threshold parameters which govern the existence and stability of all equilibria of the model. We explore the global asymptotic stability of all equilibria by utilizing Lyapunov function and Lyapunov–LaSalle asymptotic stability theorem. We have presented numerical simulations to justify the applicability and effectiveness of the theoretical results. In addition, we evaluate the effect of HTLV-I infection on the HIV dynamics and vice versa.

Keywords HIV/HTLV-I co-infection \cdot Global stability \cdot Mitotic transmission \cdot CTL-mediated immune response \cdot Lyapunov function

Extended author information available on the last page of the article
1 Introduction

Nowadays, humans are vulnerable to infection with many different viruses such as human immunodeficiency virus (HIV), human T-lymphotropic virus type I (HTLV-I), hepatitis B virus (HBV), hepatitis C virus (HCV), dengue virus and lastly coronavirus. These viruses cause many fatal diseases. HIV is a retrovirus that infects the susceptible CD4\(^+\) T cell and destroys its functions. Acquired immunodeficiency syndrome (AIDS) is the advanced stage of HIV infection. An individual can be infected with HIV by direct contact with certain body fluids (blood, semen (cum), pre-seminal fluid (pre-cum), vaginal fluids, rectal fluids and breast milk) from an HIV-infected individual. Till now, the available antiviral treatments can significantly suppress HIV replication but they can not eliminate the HIV from the body. According to global health observatory (GHO 2018) data of HIV/AIDS published by WHO [1] that says, globally, about 37.9 million HIV-infected people in 2018, 1.7 million newly HIV-infected and 770,000 HIV-related death in the same year. During the last decades, mathematical modeling of within-host HIV infection has witnessed a significant development. Nowak and Bangham [2] have introduced an initial HIV infection model to describe the interaction between three compartments, susceptible CD4\(^+\) T cells (S), active HIV-infected cells (I) and free HIV particles (V). Silent viral reservoirs remain one of the major hurdles for eradicating the HIV by current antiviral therapy [3]. Silent HIV-infected cells include HIV virions but do not produce them until they become activated. Mathematical modeling of HIV dynamics with silent infected cells can help in predicting the effect of antiviral drug efficacy on HIV progression [4]. Rong and Perelson [5] have included the silent infected cells in the initial HIV model presented in [2] as:

\[
\begin{align*}
\dot{S} &= \rho - zS - \eta_1 SV, \\
\dot{L} &= (1 - \beta)\eta_1 SV - (\lambda + \gamma)L, \\
\dot{I} &= \beta\eta_1 SV + \lambda L - aI, \\
\dot{V} &= bI - \varepsilon V,
\end{align*}
\]

where \(S = S(t)\), \(L = L(t)\), \(I = I(t)\) and \(V = V(t)\) are the concentrations of susceptible CD4\(^+\) T cells, silent HIV-infected cells, active HIV-infected cells and free HIV particles at time \(t\), respectively. The susceptible CD4\(^+\) T cells are produced at specific constant rate \(\rho\). The HIV virions can replicate using virus-to-cell transmission. The term \(\eta_1 SV\) refers to the rate at which new infectious appears by virus-to-cell contact between free HIV particles and susceptible CD4\(^+\) T cells. Silent HIV-infected cells are transmitted to be active at rate \(\lambda L\). The free HIV particles are generated at rate \(bI\). The natural death rates of the susceptible CD4\(^+\) T cells, silent HIV-infected cells, active HIV-infected cells and free HIV particles are given by \(zS\), \(\gamma L\), \(aI\) and \(\varepsilon V\), respectively. A fraction \(\beta \in (0, 1)\) of new HIV-infected cells will be active, and the remaining part \(1 - \beta\) will be silent. Over past decades, mathematical modeling and analysis of HIV mono-infection with both silent and active HIV-
infected cells have witnessed a significant development (see e.g., [6–13] and the review article [3]).

HTLV-I can lead to two diseases, adult T-cell leukemia (ATL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HTLV-I can be transmitted to humans from sexual contact, needle sharing, contaminated blood products and breastfeeding [14]. HTLV-I is a global epidemic that infects about 10–25 million persons [15]. The infection is endemic in the Caribbean, southern Japan, the Middle East, South America, parts of Africa, Melanesia and Papua New Guinea [16]. HTLV-I is a provirus that targets the susceptible CD4\(^+\) T cells. HTLV-I is a single-stranded RNA retrovirus that reverse transcribes its RNA genome into a proviral DNA copy which in turn reaches the host chromatin and integrates into the DNA of the host genome, at which point the virus is referred to as a provirus. Later, cell infected with this virus enters a silent period and it is not capable to produce DNA and infects susceptible cells. Although, silent HTLV-infected cells can survive for a long-lasting time, however, they may be suddenly activated by antigen and become able to infect susceptible cells. During the primary infection stage of HTLV-I, the proviral load can reach high level, approximately 30–50% [17]. Unlike the case of HIV infection, however, only a small percentage of infected individuals develop the disease and 2–5% percent of HTLV-I carriers develop symptoms of ATL and another 0.25–3% develop HAM/TSP [18]. Many researchers have been concerned to study mathematical modeling and analysis of HTLV-I mono-infection in several works [19–21].

There are some differences between HIV and HTLV-I. HIV can break free from a CD4\(^+\) T cell and infect other susceptible CD4\(^+\) T cell, while cell-free HTLV-I does not trigger infection. HTLV-I has two modes of transmission, the first is the horizontal transmission via direct cell-to-cell contact through the virological synapse [22], and the second is the vertical transmission through the mitotic division of Tax-expressing HTLV-infected cells [23]. Tax-expressing HTLV-infected cells proliferate faster than susceptible CD4\(^+\) T cells and silent HTLV-infected cells. This leads to an increase of proviral load. Therefore, vertical mitotic transmission plays an important role in the persistence of HTLV-I infection [23]. Li and Lim [24] have formulated an HTLV-I dynamics model that takes into account both horizontal and vertical routes of transmission as:

\[
\begin{align*}
\dot{S} &= \rho - \alpha S - \eta_2 SY, \\
\dot{E} &= \phi \eta_2 SY + \kappa r^* \left( 1 - \frac{S + E}{K} \right) - (\psi + \omega) E, \\
\dot{Y} &= \psi E - \delta^* Y,
\end{align*}
\]

where \( S = S(t), \ E = E(t) \) and \( Y = Y(t) \) are the concentrations of susceptible CD4\(^+\) T cells, silent HTLV-infected cells and Tax-expressing HTLV-infected cells, at time \( t \), respectively. The rate at which new infectious appears by cell-to-cell contact between Tax-expressing HTLV-infected cells and susceptible CD4\(^+\) T cells is assumed to be \( \eta_2 SY \). The fraction \( \phi \in (0, 1) \) is the probability of new HTLV infections via horizontal transmission could enter a silent period. The other route of transmission for HTLV is the vertical caused by selective expansion of Tax-
expressing CD4^+ T cells that are driven into proliferation by HTLV Tax gene at a rate \( r^* Y \left( 1 - \frac{S + E}{K} \right) \), where \( K \) is the CD4^+ T cells carrying capacity. The term \( \kappa r^* Y \left( 1 - \frac{S + E}{K} \right) \) accounts for the HTLV-infected cells that being silent and, therefore, escaping from the immune system, where \( \kappa \in (0, 1) \). The natural death rates of the silent HTLV-infected cells and Tax-expressing HTLV-infected cells are represented by \( \omega E \) and \( \delta^* Y \), respectively. The term \( \psi E \) accounts for the rate of silent HTLV-infected cells that become Tax-expressing HTLV-infected cells. Asquith and Bangham [25] have been reported that, even in the presence of rapid selective mitotic division, target cell populations are less than the total CD4^+ T cells carrying capacity i.e. \( S + E < K \). Therefore, Lim and Maini [15] have replaced the logistic term \( r^* Y \left( 1 - \frac{S + E}{K} \right) \) by an exponential growth term \( r^* Y \).

Cytotoxic T lymphocytes (CTLs) are recognized as the significant component of the human immune response against viral infections. CTLs inhibit viral replication and kill the cells which are infected by viruses. In fact, CTLs and antibodies are necessary and universal to control HIV infection for years [26]. The incorporation of the immune response in the HIV dynamics models gives us a better understanding of within-host HIV dynamics. During recent years, great efforts have been made to formulate and analyze the within-host HIV mono-infection models under the influence of CTL immune response (see e.g. [2] and [27]). In [28, 29], silent HIV-infected cells have been included in the HIV dynamics models with CTL immune response. In the case of HTLV-I infection, it has been reported in [25] and [30] that the CTLs play an effective role in controlling such infection. CTLs can recognize and kill the Tax-expressing HTLV-infected cells, moreover, they can reduce the proviral load. In the literature, several mathematical models have been proposed to describe the dynamics of HTLV-I under the effect of CTL immune response (see e.g. [16] and [31–34]). HTLV-I dynamics models with the mitotic division of Tax-expressing HTLV-infected cells and CTL immune response have been developed in [15, 35–37]. Li and Zhou [36] have assumed that Tax-expressing HTLV-infected cells proliferate at rate \( r^* Y \), with \( (1 - \kappa) r^* Y \) staying in the Tax-expressing HTLV-infected cells compartment, while \( \kappa r^* Y \) being silent and, therefore, escaping from the immune system.

Simultaneous infection by HIV and HTLV-I and the etiology of their pathogenic and disease outcomes have become a global health matter over the past 10 years. The importance of studying HIV/HTLV-I co-infection comes from the fact that both viruses share the same ways of transmission in a population as mentioned above. This means that co-infection with both viruses can occurred in the areas where both viruses are endemic [38]. Although CD4^+ T cells are the major targets of both HIV and HTLV-I, however, these viruses present a different biological behavior that causes diverse impacts on host immunity and ultimately leads to numerous clinical diseases [39]. It has been reported that the HTLV-I co-infection rate among HIV infected patients as increase as 100 to 500 times in comparison with the general population [40]. In seroepidemiologic studies, it has been recorded that HIV-infected patients are more exposure to be co-infected with HTLV-I, and vice versa compared to the general population [41]. HIV/HTLV-I co-infection is usually found in individuals of specific ethnic or who belonged to geographic origins where these
viruses are simultaneously endemic [42]. As an example, the co-infection rates in individuals living in Bahia have reached 16% of HIV-infected patients [43]. The prevalence of dual infection with HIV and HTLV-I has become more widely in several geographical regions throughout the world such as South America, Europe, the Caribbean, Bahia (Brazil), Mozambique (Africa), and Japan [41, 43]. HIV and HTLV-I dual infection appears to have an overlap on the course of associated clinical outcomes with both viruses [41]. Several reports have concluded that HIV/HTLV-I co-infected patients were found to have an increase of CD4\(^+\) T cells count in comparison with HIV mono-infected patients, although there is no evident to result in a better immune response [39, 44]. Indeed, simultaneously infected patients by both viruses with CD4\(^+\) T counts greater than 200 cells/mm\(^3\) are more exposure to have other opportunistic infections as compared with HIV mono-infected patients who have similar CD4\(^+\) T counts [44]. Studies have reported that higher mortality and shortened survival rates were accompany with co-infected individuals more than mono-infected individuals [45]. Considering the natural history of HIV, many researchers have noted that co-infection with HIV and HTLV-I can accelerate the clinical progression to AIDS. On the other hand, HIV can adjust HTLV-I expression in co-infected individuals which leads them to a higher risk of developing HTLV-I related diseases such as ATL and TSP/HAM [40, 41, 45].

Although a great number of mathematical HIV and HTLV-I mono-infections models has been developed and analyzed, however, to the best of our knowledge there is no mathematical model for HIV/HTLV-I co-infection. Therefore, our aim in the present paper is to formulate a new HIV/HTLV-I co-infection model. The HIV can spread via virus-to-cell transmission, while HTLV-I has two routes of transmission, (i) horizontal transmission via direct cell-to-cell contact through the virological synapse, and (ii) vertical transmission through the mitotic division of Tax-expressing HTLV-infected cells. We first show that the model is well-posed by establishing that the solutions of the model are nonnegative and bounded. We calculate all equilibria and derive a set of threshold parameters which govern the existence and stability of the equilibria of the model. We study the global stability of equilibria by constructing suitable Lyapunov functions and utilizing Lyapunov–LaSalle asymptotic stability theorem. We conduct some numerical simulations to illustrate the theoretical results.

We remark that, our proposed HIV/HTLV-I co-infection model can be developed and extended to incorporate different biological phenomena such as intracellular time delay [46–50], reaction-diffusion [51, 52] and stochastic interactions [53].

2 Model formulation

We set up an ordinary differential equation (ODE) model that describes the change of concentrations of eight compartments with respect to time \( t \); susceptible (uninfected) CD4\(^+\) T cells \( S(t) \), silent HIV-infected cells \( L(t) \), active HIV-infected cells \( I(t) \), silent HTLV-infected cells \( E(t) \), Tax-expressing HTLV-infected cells \( Y(t) \), free HIV particles \( V(t) \), HIV-specific CTLs \( C^H(t) \) and HTLV-specific CTLs \( C^Y(t) \). The dynamics of HIV/HTLV-I co-infection is schematically shown in the transfer diagram given in Fig. 1.
Our proposed model is given by the following system of ODEs:

\[
\begin{align*}
\dot{S} &= \rho - \alpha S - \eta_1 SV - \eta_2 SY, \\
\dot{L} &= (1 - \beta) \eta_1 SV - (\lambda + \gamma) L, \\
\dot{I} &= \beta \eta_1 SV + \lambda L - a I - \mu_1 CI, \\
\dot{E} &= \phi \eta_2 SY + \kappa r^* Y - (\psi + \omega) E, \\
\dot{Y} &= \psi E + (1 - \kappa) r^* Y - \delta^* Y - \mu_2 CY Y, \\
\dot{V} &= b I - \epsilon V, \\
\dot{C^I} &= \sigma_1 C^I I - \pi_1 C^I, \\
\dot{C^Y} &= \sigma_2 C^Y Y - \pi_2 C^Y,
\end{align*}
\]

where \((S, L, I, E, Y, V, C^I, C^Y) = (S(t), L(t), I(t), E(t), Y(t), V(t), C^I(t), C^Y(t))\). The term \(\mu_1 C^I I\) is the killing rate of active HIV-infected cells due to their specific immunity. The term \(\mu_2 C^Y Y\) is the killing rate of Tax-expressing HTLV-infected cells due to their specific immunity. The proliferation and death rates for both effective HIV-specific CTLs and HTLV-specific CTLs are given by \(\sigma_1 C^I I\), \(\sigma_2 C^Y Y\), \(\pi_1 C^I\) and \(\pi_2 C^Y\), respectively. All remaining parameters have the same biological meaning as explained in the previous section. Table 1 summarizes all parameters and their definitions.

In [15], it is assumed that \(r^* < v^* = \min\{\alpha, \omega, \delta^*\}\), which corresponds to experimental evidence indicating that the proliferation rate of HTLV-infected cells is generally lower than the rate of removal due to natural death. Since \(r^* < \delta^*\) and \(0 < \kappa < 1\), then \((1 - \kappa) r^* < \delta^*\) and

\[
\delta^* - (1 - \kappa) r^* > 0.
\]

Let \(\delta = \delta^* - (1 - \kappa) r^*\) and \(r = \kappa r^*\). Then, system (3) will take the following form of ODEs:

\[
\begin{align*}
\dot{S} &= \rho - \alpha S - \eta_1 SV - \eta_2 SY, \\
\dot{L} &= (1 - \beta) \eta_1 SV - (\lambda + \gamma) L, \\
\dot{I} &= \beta \eta_1 SV + \lambda L - a I - \mu_1 CI, \\
\dot{E} &= \phi \eta_2 SY + \kappa r^* Y - (\psi + \omega) E, \\
\dot{Y} &= \psi E + (1 - \kappa) r^* Y - \delta^* Y - \mu_2 CY Y, \\
\dot{V} &= b I - \epsilon V, \\
\dot{C^I} &= \sigma_1 C^I I - \pi_1 C^I, \\
\dot{C^Y} &= \sigma_2 C^Y Y - \pi_2 C^Y,
\end{align*}
\]

Fig. 1 The schematic diagram of the HIV/HTLV-I co-infection dynamics in vivo

Birkhäuser
\[ S = \rho - \alpha S - \eta_1 SV - \eta_2 SY, \]
\[ L = (1 - \beta) \eta_1 SV - (\lambda + \gamma)L, \]
\[ \dot{I} = \beta \eta_1 SV + \lambda L - a I - \mu_1 C^I I, \]
\[ \dot{E} = \phi \eta_2 SY + r Y - (\psi + \omega)E, \]
\[ \dot{Y} = \psi E - \delta Y - \mu_2 C^Y Y, \]
\[ \dot{V} = b I - \varepsilon V, \]
\[ C^I = \sigma_1 C^I I - \pi_1 C^I, \]
\[ C^Y = \sigma_2 C^Y Y - \pi_2 C^Y. \]

3 Preliminaries

Let \( \Omega_j > 0, j = 1, \ldots, 5 \) and define
\[ \Theta = \{ (S, L, I, E, Y, V, C', C') \in \mathbb{R}^8_{\geq 0} : 0 \leq S(t), L(t), I(t) \leq \Omega_1, \\
0 \leq E(t), Y(t) \leq \Omega_2, 0 \leq V(t) \leq \Omega_3, 0 \leq C'(t) \leq \Omega_4, 0 \leq C''(t) \leq \Omega_5 \} . \]

**Proposition 1** The compact set \( \Theta \) is positively invariant for system (4).

**Proof** We have

\[
\dot{S} \mid_{S=0} = \rho > 0, \quad \dot{L} \mid_{L=0} = (1 - \beta) \eta_1 SV \geq 0 \quad \text{for all } S, V \geq 0,
\]

\[
\dot{I} \mid_{I=0} = \beta \eta_1 SV + \lambda L \geq 0 \quad \text{for all } S, V, L \geq 0, \quad \dot{E} \mid_{E=0} = \phi \eta_2 SY + rY \quad \text{for all } S, Y \geq 0,
\]

\[
\dot{Y} \mid_{Y=0} = \psi E \geq 0 \quad \text{for all } E \geq 0, \quad \dot{V} \mid_{V=0} = bI \geq 0 \quad \text{for all } I \geq 0,
\]

\[
C' \mid_{C'=0} = 0, \quad C'' \mid_{C''=0} = 0.
\]

This insures that, \( (S(t), L(t), I(t), E(t), Y(t), V(t), C'(t), C''(t)) \in \mathbb{R}^8_{\geq 0} \) for all \( t \geq 0 \) when \( (S(0), L(0), I(0), E(0), Y(0), V(0), C'(0), C''(0)) \in \mathbb{R}^8_{\geq 0} \). To show the boundedness of all state variables, we let

\[
\Psi(t) = S + L + I + \frac{1}{\phi} (E + Y) + \frac{a}{2b} V + \frac{\mu_1}{\sigma_1} C' + \frac{\mu_2}{\phi \sigma_2} C''.
\]

Then

\[
\dot{\Psi} = \rho - aS - \gamma L - \frac{a}{2} I - \omega E - \frac{(\delta - r)}{\phi} Y - \frac{ae}{2b} V - \frac{\mu_1 \pi_1}{\sigma_1} C' - \frac{\mu_2 \pi_2}{\phi \sigma_2} C''.
\]

We have \( \delta - r = \delta^* - r^* > 0 \). Hence,

\[
\dot{\Psi} = \rho - aS - \gamma L - \frac{a}{2} I - \omega E - \frac{(\delta^* - r^*)}{\phi} Y - \frac{ae}{2b} V - \frac{\mu_1 \pi_1}{\sigma_1} C' - \frac{\mu_2 \pi_2}{\phi \sigma_2} C''
\]

\[
\leq \rho - \phi \left[ S + L + I + \frac{1}{\phi} (E + Y) + \frac{a}{2b} V + \frac{\mu_1}{\sigma_1} C' + \frac{\mu_2}{\phi \sigma_2} C'' \right] = \rho - \phi \Psi,
\]

where \( \phi = \min \{ \alpha, \gamma, \frac{\omega}{\phi}, \omega, \delta^* - r^*, \varepsilon, \pi_1, \pi_2 \} \). Hence, \( 0 \leq \Psi(t) \leq \Omega_1 \) if \( \Psi(0) \leq \Omega_1 \) for \( t \geq 0 \), where \( \Omega_1 = \frac{\rho}{\phi} \). Since \( S, L, I, E, Y, V, C' \), and \( C'' \) are all nonnegative then \( 0 \leq S(t), L(t), I(t) \leq \Omega_1, 0 \leq E(t), Y(t) \leq \Omega_2, 0 \leq V(t) \leq \Omega_3, 0 \leq C'(t) \leq \Omega_4, 0 \leq C''(t) \leq \Omega_5 \) if \( S(0) + L(0) + I(0) + \frac{1}{\phi} (E(0) + Y(0)) + \frac{a}{2b} V(0) + \frac{\mu_1 \pi_1}{\sigma_1} C'(0) + \frac{\mu_2 \pi_2}{\phi \sigma_2} C''(0) \leq \Omega_1 \), where \( \Omega_2 = \phi \Omega_1, \Omega_3 = \frac{\mu_1 \pi_1}{\alpha}, \Omega_4 = \frac{\sigma_1 \Omega_1}{\mu_1} \) and \( \Omega_5 = \frac{\phi \sigma_2 \Omega_1}{\mu_2} \). \( \Box \)

**4 Threshold parameters and equilibria**

In this section, we derive eight threshold parameters which guarantee the existence of the equilibria of the model. Let \( (S, L, I, E, Y, V, C', C'') \) be any equilibrium of system (4) satisfying the following equations:

\[ ... \]
\[ 0 = \rho - \alpha S - \eta_1 SV - \eta_2 SY, \] (5)
\[ 0 = (1 - \beta)\eta_1 SV - (\lambda + \gamma)L, \] (6)
\[ 0 = \beta \eta_1 SV + \lambda L - \alpha I - \mu_1 C^I, \] (7)
\[ 0 = \varphi \eta_2 SY + \gamma Y - (\psi + \omega)E, \] (8)
\[ 0 = \psi E - \delta Y - \mu_2 C^Y Y, \] (9)
\[ 0 = bI - \varepsilon V, \] (10)
\[ 0 = (\sigma_1 I - \pi_1)C^I, \] (11)
\[ 0 = (\sigma_2 Y - \pi_2)C^Y. \] (12)

The straightforward calculation finds that system (4) admits eight equilibria.

(1) Infection-free equilibrium, \( D_0 = (S_0, 0, 0, 0, 0, 0, 0) \), where \( S_0 = \rho/\alpha \). This case describes the situation of healthy state where both HIV and HTLV-I are absent.

(2) Chronic HIV mono-infection equilibrium with inactive immune response, \( D_1 = (S_1, L_1, I_1, 0, 0, V_1, 0, 0) \), where

\[
S_1 = \frac{ae(\gamma + \lambda)}{\eta_1 b(\beta \gamma + \lambda)}, \quad L_1 = \frac{ae(1 - \beta)}{\eta_1 b(\beta \gamma + \lambda)} \left[ \frac{\eta_1 bS_0(\beta \gamma + \lambda)}{ae(\gamma + \lambda)} - 1 \right],
\[
I_1 = \frac{\varepsilon}{\eta_1} \left[ \frac{\eta_1 bS_0(\beta \gamma + \lambda)}{ae(\gamma + \lambda)} - 1 \right], \quad V_1 = \frac{\alpha}{\eta_1} \left[ \frac{\eta_1 bS_0(\beta \gamma + \lambda)}{ae(\gamma + \lambda)} - 1 \right].
\]

Therefore, \( D_1 \) exists when

\[
\frac{\eta_1 bS_0(\beta \gamma + \lambda)}{ae(\gamma + \lambda)} > 1.
\]

At the equilibrium \( D_1 \) the chronic HIV mono-infection persists while the immune response is unstimulated. The basic HIV mono-infection reproductive ratio for system (4) is defined as:

\[ R_1 = \frac{\eta_1 bS_0(\beta \gamma + \lambda)}{ae(\gamma + \lambda)}. \]

The parameter \( R_1 \) determines whether or not a chronic HIV infection can be established. In terms of \( R_1 \), we can write

\[
S_1 = \frac{S_0}{R_1}, \quad L_1 = \frac{ae(1 - \beta)}{\eta_1 b(\beta \gamma + \lambda)} (R_1 - 1), \quad I_1 = \frac{\varepsilon}{\eta_1 b} (R_1 - 1), \quad V_1 = \frac{\alpha}{\eta_1} (R_1 - 1).
\]

(3) Chronic HTLV mono-infection equilibrium with inactive immune response, \( D_2 = (S_2, 0, 0, E_2, Y_2, 0, 0, 0) \), where
\[
S_2 = \frac{(\delta - r)\psi + \delta \omega}{\eta_2 \psi}, \quad E_2 = \frac{\alpha \delta}{\eta_2 \psi} \left[ \frac{\varphi \eta_2 S_0}{(\delta - r)\psi + \delta \omega} - 1 \right],
\]
\[
Y_2 = \frac{\alpha}{\eta_2} \left[ \frac{\varphi \eta_2 S_0}{(\delta - r)\psi + \delta \omega} - 1 \right].
\]

Therefore, \( \mathcal{D}_2 \) exists when
\[
\frac{\varphi \eta_2 S_0}{(\delta - r)\psi + \delta \omega} > 1.
\]

At the equilibrium \( \mathcal{D}_2 \) the chronic HTLV mono-infection persists while the immune response is unstimulated. The basic HTLV mono-infection reproductive ratio for system (4) is defined as:
\[
\mathcal{R}_2 = \frac{\varphi \eta_2 S_0}{(\delta - r)\psi + \delta \omega}.
\]

The parameter \( \mathcal{R}_2 \) decides whether or not a chronic HTLV infection can be established. In terms of \( \mathcal{R}_2 \), we can write
\[
S_2 = \frac{S_0}{\mathcal{R}_2}, \quad E_2 = \frac{\alpha \delta}{\eta_2 \psi} (\mathcal{R}_2 - 1), \quad Y_2 = \frac{\alpha}{\eta_2} (\mathcal{R}_2 - 1).
\]

(4) Chronic HIV mono-infection equilibrium with only active HIV-specific CTL, \( \mathcal{D}_3 = (S_3, L_3, I_3, 0, 0, V_3, C'_3, 0) \), where
\[
S_3 = \frac{\varepsilon \sigma_1 \rho}{\pi_1 \eta_1 b + \varepsilon \sigma_1}, \quad L_3 = \frac{\pi_1 \eta_1 b \rho (1 - \beta)}{(\gamma + \lambda)(\pi_1 \eta_1 b + \varepsilon \sigma_1)}, \quad I_3 = \frac{\pi_1}{\sigma_1},
\]
\[
V_3 = \frac{b}{\varepsilon} I_3 = \frac{b \pi_1}{\varepsilon \sigma_1}, \quad C'_3 = \frac{a}{\mu_1} \left[ \frac{\sigma_1 \rho \eta_1 b (\beta \gamma + \lambda)}{a(\gamma + \lambda)(\pi_1 \eta_1 b + \varepsilon \sigma_1)} - 1 \right].
\]

We note that \( \mathcal{D}_3 \) exists when \( \frac{\sigma_1 \rho \eta_1 b (\beta \gamma + \lambda)}{a(\gamma + \lambda)(\pi_1 \eta_1 b + \varepsilon \sigma_1)} > 1 \). The HIV-specific CTL-mediated immunity reproductive ratio in case of HIV mono-infection is stated as:
\[
\mathcal{R}_3 = \frac{\sigma_1 \rho \eta_1 b (\beta \gamma + \lambda)}{a(\gamma + \lambda)(\pi_1 \eta_1 b + \varepsilon \sigma_1)}.
\]

Thus, \( C'_3 = \frac{a}{\mu_1} (\mathcal{R}_3 - 1) \). The parameter \( \mathcal{R}_3 \) determines whether or not the HIV-specific CTL-mediated immune response is stimulated in the absence of HTLV infection.

(5) Chronic HTLV mono-infection equilibrium with only active HTLV-specific CTL, \( \mathcal{D}_4 = (S_4, 0, 0, E_4, Y_4, 0, 0, C'_4) \), where
\[
S_4 = \frac{\sigma_2 \rho}{\pi_2 \eta_2 + x_2}, \quad Y_4 = \frac{\pi_2}{\sigma_2}, \quad E_4 = \frac{\pi_2 [r(\pi_2 \eta_2 + x_2) + \eta_2 \rho \phi \sigma_2]}{\sigma_2 (\psi + \omega)(\pi_2 \eta_2 + x_2)},
\]
\[
C^Y_4 = \frac{(\delta - r)\psi + \delta \omega}{\mu_2 (\psi + \omega)} \left[ \frac{\psi \sigma_2 \rho \phi \eta_2}{((\delta - r)\psi + \delta \omega)(\pi_2 \eta_2 + x_2)} - 1 \right].
\]

We note that \( D_4 \) exists when \( \frac{\psi \sigma_2 \rho \phi \eta_2}{((\delta - r)\psi + \delta \omega)(\pi_2 \eta_2 + x_2)} > 1 \). The HTLV-specific CTL-mediated immunity reproductive ratio in case of HTLV mono-infection is stated as:

\[
\mathcal{R}_4 = \frac{\psi \sigma_2 \rho \phi \eta_2}{((\delta - r)\psi + \delta \omega)(\pi_2 \eta_2 + x_2)}.
\]

Thus, \( C^Y_4 = \frac{(\delta - r)\psi + \delta \omega}{\mu_2 (\psi + \omega)} (\mathcal{R}_4 - 1) \). The parameter \( \mathcal{R}_4 \) determines whether or not the HTLV-specific CTL-mediated immune response is stimulated in the absence of HIV infection.

(6) Chronic HIV/HTLV co-infection equilibrium with only active HIV-specific CTL, \( D_5 = (S_5, L_5, I_5, E_5, Y_5, V_5, C^l_5, 0) \), where

\[
S_5 = \frac{(\delta - r)\psi + \delta \omega}{\rho \eta_2 \psi} = S_2, \quad I_5 = \frac{\pi_1}{\sigma_1} = I_3,
\]
\[
V_5 = \frac{b \pi_1}{\epsilon \sigma_1} = V_3, \quad L_5 = \frac{\pi_1 \eta_1 b (1 - \beta)[(\delta - r)\psi + \delta \omega]}{\epsilon \eta_2 \sigma_1 \phi \psi (\gamma + \lambda)},
\]
\[
E_5 = \frac{\delta (\pi_1 \eta_1 b + x \varepsilon_1)}{\epsilon \eta_2 \sigma_1 \psi} \left[ \frac{\rho \phi \eta_2 \sigma_1 \psi}{((\delta - r)\psi + \delta \omega)(\pi_1 \eta_1 b + x \varepsilon_1)} - 1 \right],
\]
\[
Y_5 = \frac{\pi_1 \eta_1 b + x \varepsilon_1}{\epsilon \eta_2 \sigma_1} \left[ \frac{\rho \phi \eta_2 \sigma_1 \psi}{((\delta - r)\psi + \delta \omega)(\pi_1 \eta_1 b + x \varepsilon_1)} - 1 \right],
\]
\[
C^l_5 = \frac{a}{\mu_1} \left[ \frac{\eta_1 b (\beta_1 + \lambda)[(\delta - r)\psi + \delta \omega]}{\alpha \varepsilon \eta_2 \psi (\gamma + \lambda)} - 1 \right] = \frac{a}{\mu_1} (\mathcal{R}_1 / \mathcal{R}_2 - 1).
\]

We note that \( D_5 \) exists when \( \mathcal{R}_1 / \mathcal{R}_2 > 1 \) and \( \frac{\rho \phi \eta_2 \sigma_1 \psi}{((\delta - r)\psi + \delta \omega)(\pi_1 \eta_1 b + x \varepsilon_1)} > 1 \). The HTLV infection reproductive ratio in the presence of HIV infection is stated as:

\[
\mathcal{R}_5 = \frac{\rho \phi \eta_2 \sigma_1 \psi}{((\delta - r)\psi + \delta \omega)(\pi_1 \eta_1 b + x \varepsilon_1)}.
\]

The parameter \( \mathcal{R}_5 \) determines whether or not HIV-infected patients could be co-infected with HTLV. Thus, \( E_5 = \frac{\delta (\pi_1 \eta_1 b + x \varepsilon_1)}{\epsilon \eta_2 \sigma_1 \psi} (\mathcal{R}_5 - 1) \), \( Y_5 = \frac{\pi_1 \eta_1 b + x \varepsilon_1}{\epsilon \eta_2 \sigma_1} (\mathcal{R}_5 - 1) \).

(7) Chronic HIV/HTLV co-infection equilibrium with only active HTLV-specific CTL, \( D_6 = (S_6, L_6, I_6, E_6, Y_6, V_6, 0, C^Y_6) \), where
It is obvious that $D_6$ exists when $R_2/R_1 > 1$ and $\frac{\rho b \eta_1 \sigma_2 (\beta'_y + \lambda)}{a e (\gamma + \lambda) (\pi_2 \eta_2 + \alpha \sigma_2)} > 1$. The HIV infection reproductive ratio in the presence of HTLV infection is stated as:

$$R_6 = \frac{\rho b \eta_1 \sigma_2 (\beta'_y + \lambda)}{a e (\gamma + \lambda) (\pi_2 \eta_2 + \alpha \sigma_2)}.$$ 

Thus,

$$L_6 = \frac{a e (1 - \beta)(\pi_2 \eta_2 + \alpha \sigma_2)}{b \eta_1 \sigma_2 (\beta'_y + \lambda)} (R_6 - 1), \quad I_6 = \frac{e(\pi_2 \eta_2 + \alpha \sigma_2)}{b \eta_1 \sigma_2} (R_6 - 1), \quad V_6 = \frac{\pi_2 \eta_2 + \alpha \sigma_2}{\eta_1 \sigma_2} (R_6 - 1).$$

The parameter $R_6$ determines whether or not HTLV-infected patients could be co-infected with HIV.

(8) Chronic HIV/HTLV co-infection equilibrium with active HIV-specific CTL and HTLV-specific CTL, $D_7 = (S_7, L_7, I_7, E_7, Y_7, V_7, C_7, C'_7)$, where

$$S_7 = \frac{e \xi \sigma_1 \sigma_2 \rho}{\pi_1 \eta_1 b \sigma_2 + \pi_2 \eta_2 e \sigma_1 + \alpha \sigma_1 \sigma_2},$$

$$L_7 = \frac{e \xi \sigma_1 \sigma_2 \rho (1 - \beta)}{(\gamma + \lambda)(\pi_1 \eta_1 b \sigma_2 + \pi_2 \eta_2 e \sigma_1 + \alpha \sigma_1 \sigma_2)},$$

$$E_7 = \frac{\pi_2 \eta_1 \sigma_1 (\pi_1 \eta_1 b \sigma_2 + \pi_2 \eta_2 e \sigma_1 + \alpha \sigma_1 \sigma_2 + \eta_2 e \sigma_1 \sigma_2 \rho \theta)}{\sigma_2 (\psi + \omega)(\pi_1 \eta_1 b \sigma_2 + \pi_2 \eta_2 e \sigma_1 + \alpha \sigma_1 \sigma_2)},$$

$$I_7 = \frac{\pi_1 \eta_1 \sigma_1}{\sigma_2} = I_3, \quad Y_7 = \frac{\pi_2 \eta_2}{\sigma_2} = Y_4 = Y_6, \quad V_7 = \frac{b \eta_1}{\sigma_1} = V_3 = V_5,$$

$$C_7' = \frac{a}{\mu_1} \left[ \frac{\eta_1 b \sigma_1 \sigma_2 \rho (\beta'_y + \lambda)}{a (\gamma + \lambda)(\pi_1 \eta_1 b \sigma_2 + \pi_2 \eta_2 e \sigma_1 + \alpha \sigma_1 \sigma_2) - 1} \right],$$

$$C'_7 = \frac{e \xi \sigma_1 \sigma_2 \rho (\beta'_y + \lambda)}{a (\gamma + \lambda)(\pi_1 \eta_1 b \sigma_2 + \pi_2 \eta_2 e \sigma_1 + \alpha \sigma_1 \sigma_2) - 1}.$$
\begin{align*}
\psi \phi \eta_2 \varepsilon_1 \sigma_2 \rho \\
\frac{\left(\delta - r\right) \psi + \delta \omega}{\left(\pi_1 \eta_1 b \sigma_2 + \pi_2 \eta_2 \varepsilon_1 + \varepsilon \sigma_1 \sigma_2 \right)} > 1. \text{ Now we define}
\end{align*}

\begin{align*}
\mathcal{R}_7 &= \frac{\eta_1 b \sigma_1 \sigma_2 \rho \left(\beta \gamma + \lambda\right)}{a \left(\gamma + \lambda\right)\left(\pi_1 \eta_1 b \sigma_2 + \pi_2 \eta_2 \varepsilon_1 + \varepsilon \sigma_1 \sigma_2 \right)}, \\
\mathcal{R}_8 &= \frac{\psi \phi \eta_2 \varepsilon_1 \sigma_2 \rho}{\left(\delta - r\right) \psi + \delta \omega}\left(\pi_1 \eta_1 b \sigma_2 + \pi_2 \eta_2 \varepsilon_1 + \varepsilon \sigma_1 \sigma_2 \right).
\end{align*}

Clearly, \( \mathcal{D}_7 \) exists when \( \mathcal{R}_7 > 1 \) and \( \mathcal{R}_8 > 1 \) and we can write \( C_7^I = \frac{a}{\mu_1} (\mathcal{R}_7 - 1) \) and \( C_7^T = \frac{(\delta - r) \psi + \delta \omega}{\mu_2 (\psi + \omega)} (\mathcal{R}_8 - 1) \). The parameter \( \mathcal{R}_7 \) refers to the competed HIV-specific CTL-mediated immunity reproductive ratio in case of HIV/HTLV co-infection. On the other hand, the parameter \( \mathcal{R}_8 \) refers to the competed HTLV-specific CTL-mediated immunity reproductive ratio in case of HIV/HTLV co-infection.

The eight threshold parameters are given as follows:

\begin{align*}
\mathcal{R}_1 &= \frac{\eta_1 b S_0 \left(\beta \gamma + \lambda\right)}{a e (\gamma + \lambda)}, \quad \mathcal{R}_2 = \frac{\phi \eta_2 S_0}{\left(\delta - r\right) \psi + \delta \omega}, \quad \mathcal{R}_3 = \frac{\sigma_1 \rho \eta_1 b \left(\beta \gamma + \lambda\right)}{a (\gamma + \lambda)\left(\pi_1 \eta_1 b + \varepsilon \sigma_1 \sigma_2 \right)}, \\
\mathcal{R}_4 &= \frac{\psi \sigma_2 \rho \eta_2}{\left(\delta - r\right) \psi + \delta \omega}\left(\pi_2 \eta_2 + \varepsilon \sigma_2 \right), \quad \mathcal{R}_5 = \frac{\rho \phi \varepsilon_2 \sigma_1 \psi}{\left(\delta - r\right) \psi + \delta \omega}\left(\pi_1 \eta_1 b + \varepsilon \sigma_1 \sigma_2 \right), \\
\mathcal{R}_6 &= \frac{\rho b \eta_1 \sigma_2 \left(\beta \gamma + \lambda\right)}{a e (\gamma + \lambda)\left(\pi_2 \eta_2 + \varepsilon \sigma_2 \right)}, \quad \mathcal{R}_7 = \frac{\eta_1 b \sigma_1 \sigma_2 \rho \left(\beta \gamma + \lambda\right)}{a (\gamma + \lambda)\left(\pi_1 \eta_1 b \sigma_2 + \pi_2 \eta_2 \varepsilon_1 + \varepsilon \sigma_1 \sigma_2 \right)}, \\
\mathcal{R}_8 &= \frac{\psi \phi \eta_2 \varepsilon_1 \sigma_2 \rho}{\left(\delta - r\right) \psi + \delta \omega}\left(\pi_1 \eta_1 b \sigma_2 + \pi_2 \eta_2 \varepsilon_1 + \varepsilon \sigma_1 \sigma_2 \right).
\end{align*}

According to the above discussion, we sum up the existence conditions for all equilibria in Table 2.

## 5 Global stability analysis

In this section, we prove the global asymptotic stability of all equilibria by constructing Lyapunov function and applying Lyapunov–LaSalle asymptotic stability theorem [54–56]. We will use the arithmetic-geometric mean inequality

\[ \frac{1}{n} \sum_{i=1}^{n} \chi_i \geq \sqrt[n]{\prod_{i=1}^{n} \chi_i}, \quad \chi_i \geq 0, \quad i = 1, 2, \ldots \]

which yields

\[ \frac{S_j}{S} + \frac{SV_I_j}{S_j V_I} + \frac{IV_j}{I_j V} \geq 3, \quad j = 1, 3, 5, 6, 7, \]  

\[ \mathcal{S} \text{ Birkhäuser} \]
Table 2 Model (4) equilibria and their existence conditions

| Equilibrium point | Definition | Existence conditions |
|-------------------|------------|----------------------|
| $D_0 = (S_0, 0, 0, 0, 0, 0, 0)$ | Infection-free equilibrium | None |
| $D_1 = (S_1, L_1, I_1, 0, 0, V_1, 0, 0)$ | Chronic HIV mono-infection equilibrium with inactive immune response | $\mathcal{R}_1 > 1$ |
| $D_2 = (S_2, 0, 0, E_2, Y_2, 0, 0, 0)$ | Chronic HTLV mono-infection equilibrium with inactive immune response | $\mathcal{R}_2 > 1$ |
| $D_3 = (S_3, L_3, I_3, 0, 0, V_3, C^d_3, 0)$ | Chronic HIV mono-infection equilibrium with only active HIV-specific CTL | $\mathcal{R}_3 > 1$ |
| $D_4 = (S_4, 0, 0, E_4, Y_4, 0, 0, C^d_4)$ | Chronic HTLV mono-infection equilibrium with only active HTLV-specific CTL | $\mathcal{R}_4 > 1$ |
| $D_5 = (S_5, L_5, I_5, E_5, Y_5, V_5, C^d_5, 0)$ | Chronic HIV/HTLV co-infection equilibrium with only active HIV-specific CTL | $\mathcal{R}_5 > 1$ and $\mathcal{R}_1 / \mathcal{R}_2 > 1$ |
| $D_6 = (S_6, L_6, I_6, E_6, Y_6, V_6, 0, C^d_6)$ | Chronic HIV/HTLV co-infection equilibrium with only active HTLV-specific CTL | $\mathcal{R}_6 > 1$ and $\mathcal{R}_2 / \mathcal{R}_1 > 1$ |
| $D_7 = (S_7, L_7, I_7, E_7, Y_7, V_7, C^d_7, C^r_7)$ | Chronic HIV/HTLV co-infection equilibrium with active HIV-specific CTL and HTLV-specific CTL | $\mathcal{R}_7 > 1$ and $\mathcal{R}_8 > 1$ |

\[
\frac{S_j}{S} + \frac{S L_j}{S_j V_j L} + \frac{L j_j}{L_j I} + \frac{I V_j}{I_j V} \geq 4, \quad j = 1, 3, 5, 6, 7, \quad (14)
\]

\[
\frac{S_j}{S} + \frac{S Y E_j}{S_j Y_j E} + \frac{E Y_j}{E_j Y} \geq 3, \quad j = 2, 4, 5, 6, 7. \quad (15)
\]

Let a function $\Phi_j(S, L, I, E, Y, V, C^d, C^r)$ and $\mathcal{Y}_j$ be the largest invariant subset of

\[
\mathcal{Y}_j = \left\{ (S, L, I, E, Y, V, C^d, C^r) : \frac{d\Phi_j}{dt} = 0 \right\}, \quad j = 0, 1, 2, \ldots, 7.
\]

We define a function

\[
F(v) = v - 1 - \ln v.
\]

**Theorem 1** If $\mathcal{R}_1 \leq 1$ and $\mathcal{R}_2 \leq 1$, then $D_0$ is globally asymptotically stable (G.A.S).

**Proof** Constructing a Lyapunov function candidate $\Phi_0(S, L, I, E, Y, V, C^d, C^r)$:

\[
\Phi_0 = S_0 F \left( \frac{S}{S_0} \right) + \frac{\lambda}{\beta_\gamma + \lambda} L + \frac{\gamma + \lambda}{\beta_\gamma + \lambda} I + \frac{1}{c} E + \frac{\psi + \omega}{\varphi \psi} Y
\]

\[
+ \frac{a(\gamma + \lambda)}{b(\beta_\gamma + \lambda)} V + \mu_1(\gamma + \lambda) C^d + \mu_2(\psi + \omega) \frac{\varphi \psi \sigma_2}{C^r}
\]

It is seen that, $\Phi_0(S, L, I, E, Y, V, C^d, C^r) > 0$ for all $S, L, I, E, Y, V, C^d, C^r > 0$, and
\( \Phi_0 \) has a global minimum at \( \mathcal{D}_0 \). We calculate \( \frac{d\Phi_0}{dt} \) along the solutions of model (4) as:

\[
\frac{d\Phi_0}{dt} = \left( 1 - \frac{S_0}{S} \right) \left[ \rho - \alpha S - \eta_1 SV - \eta_2 SY \right] + \frac{\lambda}{\beta_\gamma + \lambda} \left[ (1 - \beta) \eta_1 SV - (\lambda + \gamma)L \right] + \frac{\gamma + \lambda}{\beta_\gamma + \lambda} \left[ \beta \eta_1 SV + \lambda L - aI - \mu_1 C'I \right] + \frac{1}{\varphi} \left[ \varphi \eta_2 SY + rY - (\psi + \omega)E \right] + \frac{\psi + \omega}{\varphi \psi} \left[ \psi E - \delta Y - \mu_2 C'Y \right] + \frac{a(\gamma + \lambda)}{b(\beta_\gamma + \lambda)} [bI - \varphi E] + \frac{\mu_1(\gamma + \lambda)}{\sigma_1(\beta_\gamma + \lambda)} \left( \sigma_1 C'I - \pi_1 C' \right) + \frac{\mu_2(\psi + \omega)}{\varphi \psi \sigma_2} \left[ \sigma_2 C'Y - \pi_2 C'Y \right] = \left( 1 - \frac{S_0}{S} \right) (\rho - \alpha S) + \eta_1 S_0 V + \eta_2 S_0 Y + \frac{r}{\varphi} Y - \delta(\psi + \omega) Y - \frac{a(\gamma + \lambda)}{b(\beta_\gamma + \lambda)} V
\]

\[
= \left( 1 - \frac{S_0}{S} \right) (\rho - \alpha S) + \eta_1 S_0 V + \eta_2 S_0 Y + \frac{r}{\varphi} Y - \delta(\psi + \omega) Y - \frac{a(\gamma + \lambda)}{b(\beta_\gamma + \lambda)} V
\]

Using \( S_0 = \rho / \alpha \), we obtain

\[
\frac{d\Phi_0}{dt} = -\alpha \left( S - S_0 \right)^2 + \frac{ae(\gamma + \lambda)}{b(\beta_\gamma + \lambda)} \left( \mathcal{R}_1 - 1 \right) V + \frac{(\delta - r)\psi + \delta \omega}{\varphi \psi} \left( \mathcal{R}_2 - 1 \right) Y - \frac{\mu_1 \pi_1 (\gamma + \lambda)}{\sigma_1(\beta_\gamma + \lambda)} C'I - \frac{\mu_2 \pi_2 (\psi + \omega)}{\varphi \psi \sigma_2} \sigma_2 C'Y.
\]

Therefore, \( \frac{d\Phi_0}{dt} \leq 0 \) for all \( S, Y, V, C'I, C'Y > 0 \), where \( \frac{d\Phi_0}{dt} = 0 \) occurs at \( S = S_0 \) and \( V = Y = C'I = C'Y = 0 \). The solutions of system (4) are confined to \( \mathcal{Y}_0 \). The set \( \mathcal{Y}_0 \) contains elements with \( Y = V = 0 \) and then \( \dot{Y} = \dot{V} = 0 \). The fifth and sixth equations of system (4) imply

\[
0 = \dot{Y} = \psi E,
\]
\[
0 = \dot{V} = bI.
\]

Hence, \( E(t) = I(t) = 0 \) for all \( t \). In addition, from the third equation of system (4) we have

\[
0 = \dot{I} = \lambda L,
\]

which yields \( L(t) = 0 \) for all \( t \). Therefore, \( \mathcal{Y}'_0 = \{ \mathcal{D}_0 \} \) and applying Lyapunov–LaSalle asymptotic stability theorem \([54–56]\) we get that \( \mathcal{D}_0 \) is G.A.S. \( \Box \)

**Theorem 2** If \( \mathcal{R}_1 > 1, \mathcal{R}_2 / \mathcal{R}_1 \leq 1 \) and \( \mathcal{R}_3 \leq 1 \), then \( \mathcal{D}_1 \) is G.A.S.

**Proof** Define a function \( \Phi_1(S, L, I, E, Y, V, C', C'Y) \) as:
\[ \Phi_1 = S_1 F \left( \frac{S}{S_1} \right) + \frac{\lambda}{\beta \gamma + \lambda} L_1 F \left( \frac{L}{L_1} \right) + \frac{\gamma + \lambda}{\beta \gamma + \lambda} I_1 F \left( \frac{I}{I_1} \right) + \frac{1}{\varphi} E \frac{\psi + \omega}{\varphi \psi} Y + \frac{\alpha(\gamma + \lambda)}{b(\beta \gamma + \lambda)} V_1 F \left( \frac{V}{V_1} \right) + \frac{\mu_1(\gamma + \lambda)}{\sigma_1(\beta \gamma + \lambda)} C^I + \frac{\mu_2(\psi + \omega)}{\varphi \psi \sigma_2} C^Y. \]

Calculating \( \frac{d\Phi_1}{dt} \) as:

\[
\frac{d\Phi_1}{dt} = \left( 1 - \frac{S_1}{S} \right) \left[ \rho - \alpha S - \eta_1 SV - \eta_2 SY \right] + \frac{\lambda}{\beta \gamma + \lambda} \left( 1 - \frac{L_1}{L} \right) \\
\times \left[ (1 - \beta) \eta_1 SV - (\lambda + \gamma)L \right] + \frac{\gamma + \lambda}{\beta \gamma + \lambda} \left( 1 - \frac{I_1}{I} \right) \left[ \beta \eta_1 SV + \lambda L - aI - \mu_1 C^I \right] \\
+ \frac{1}{\varphi} \left[ \varphi \eta_2 SY + rY - (\psi + \omega)E \right] + \frac{\psi + \omega}{\varphi \psi} \left[ \psi E - \delta Y - \mu_2 C^Y Y \right] + \frac{\alpha(\gamma + \lambda)}{b(\beta \gamma + \lambda)} \left( 1 - \frac{V_1}{V} \right) \left[ bI - \varepsilon V \right] \\
+ \frac{\mu_1(\gamma + \lambda)}{\sigma_1(\beta \gamma + \lambda)} \left[ \sigma_1 C^I - \pi_1 C^I \right] + \frac{\mu_2(\psi + \omega)}{\varphi \psi \sigma_2} \left[ \sigma_2 C^Y Y - \pi_2 C^Y \right] \\
= \left( 1 - \frac{S_1}{S} \right) \left( \rho - \alpha S \right) + \eta_1 S_1 V + \eta_2 S_1 Y - \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 SV \frac{L_1}{L} + \frac{\lambda(\gamma + \lambda)}{\beta \gamma + \lambda} \frac{L_1}{L} \\
- \frac{\beta(\gamma + \lambda)}{\beta \gamma + \lambda} \eta_1 SV \frac{I_1}{I} - \frac{\lambda(\gamma + \lambda)}{\beta \gamma + \lambda} L \frac{I_1}{I} + \frac{\alpha(\gamma + \lambda)}{\beta \gamma + \lambda} I_1 + \frac{\mu_1(\gamma + \lambda)}{\beta \gamma + \lambda} C^I I_1 \\
+ \frac{r}{\varphi} Y - \frac{\delta(\psi + \omega)}{\varphi \psi} Y - \frac{\alpha(\gamma + \lambda)}{b(\beta \gamma + \lambda)} V - \frac{\alpha(\gamma + \lambda)}{b(\beta \gamma + \lambda)} \frac{V_1}{V} + \frac{\alpha(\gamma + \lambda)}{b(\beta \gamma + \lambda)} \frac{V_1}{V} \\
- \frac{\mu_1 \pi_1(\gamma + \lambda)}{\sigma_1(\beta \gamma + \lambda)} C^I - \frac{\mu_2 \pi_2(\psi + \omega)}{\varphi \psi \sigma_2} C^Y.
\]

Using the equilibrium conditions for \( D_1 \), we get

\[
\rho = \alpha S_1 + \eta_1 S_1 V_1, \quad \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_1 V_1 = \frac{\lambda(\gamma + \lambda)}{\beta \gamma + \lambda} L_1,
\]

\[
\eta_1 S_1 V_1 = \frac{\alpha(\gamma + \lambda)}{b(\beta \gamma + \lambda)} I_1 = \frac{\alpha(\gamma + \lambda)}{b(\beta \gamma + \lambda)} V_1.
\]

Then, we obtain
\[ \frac{d\Phi_1}{dt} = \left(1 - \frac{S_t}{S}\right) (xS_1 - xS) + \eta_1S_1V_1 \left(1 - \frac{S_t}{S}\right) + \eta_2S_1Y - \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1S_1V_1 \frac{SVL_1}{S_1V_1L} + \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1S_1V_1 \frac{SVI_1}{S_1V_1I} - \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1S_1V_1 \frac{LL_1}{L_1I} + \eta_1S_1V_1 + \frac{\mu_1 (\gamma + \lambda)}{\beta \gamma + \lambda} C^I + \frac{r}{\phi} Y - \frac{\delta(\psi + \omega)}{\phi \psi} Y - \eta_1S_1V_1 \frac{IV_1}{I_1V} + \eta_1S_1V_1 - \frac{\mu_1 \pi_1 (\gamma + \lambda)}{\sigma_1 (\beta \gamma + \lambda)} C^I - \frac{\mu_2 \pi_2 (\psi + \omega)}{\phi \psi \sigma_2} C^Y \]

Therefore Eq. (16) becomes

\[ \frac{d\Phi_1}{dt} = -\alpha \left(\frac{S - S_t}{S}\right) + \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1S_1V_1 \left(4 - \frac{S_t}{S} - \frac{SVL_1}{S_1V_1L} - \frac{LL_1}{L_1I} - \frac{IV_1}{I_1V}\right) + \frac{\beta (\gamma + \lambda)}{\beta \gamma + \lambda} \eta_1S_1V_1 \left(3 - \frac{S_t}{S} - \frac{SVI_1}{S_1V_1I} - \frac{IV_1}{I_1V}\right) + \frac{\delta - r}{\phi \psi} \left(\frac{\eta_2 \psi S_1}{(\delta - r) \psi + \delta \omega} - 1\right) Y + \frac{\mu_1 \pi_1 (\gamma + \lambda)}{\sigma_1 (\beta \gamma + \lambda)} \left(\sigma_1 \frac{I_1}{I_1} - 1\right) C^I - \frac{\mu_2 \pi_2 (\psi + \omega)}{\phi \psi \sigma_2} C^Y. \]

Therefore Eq. (16) becomes

\[ \frac{d\Phi_1}{dt} = -\alpha \left(\frac{S - S_t}{S}\right) + \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1S_1V_1 \left(4 - \frac{S_t}{S} - \frac{SVL_1}{S_1V_1L} - \frac{LL_1}{L_1I} - \frac{IV_1}{I_1V}\right) + \frac{\beta (\gamma + \lambda)}{\beta \gamma + \lambda} \eta_1S_1V_1 \left(3 - \frac{S_t}{S} - \frac{SVI_1}{S_1V_1I} - \frac{IV_1}{I_1V}\right) + \frac{\left(\delta - r\right) \psi + \delta \omega}{\phi \psi} \left(\frac{\Re_2}{\Re_1} - 1\right) Y + \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\beta \gamma + \lambda)} \left(\frac{\Re_3}{\Re_1} - 1\right) C^I - \frac{\mu_2 \pi_2 (\psi + \omega)}{\phi \psi \sigma_2} C^Y. \]

Since \( \Re_2 / \Re_1 \leq 1 \) and \( \Re_3 \leq 1 \), then using inequalities (13)–(14) we get \( \frac{d\Phi}{dt} \leq 0 \) for all \( S, L, I, Y, V, C^I, C^Y > 0 \) with equality holding when \( S = S_t, L = L_t, I = I_t, V = V_1 \) and \( Y = C^I = C^Y = 0 \). The trajectories of system (4) converge to \( Y^*_I \) which includes elements with \( Y = 0 \) and then \( \dot{Y} = 0 \). The fifth equation of system (4) implies
which yields $E(t) = 0$ for all $t$. Hence, $\mathcal{Y}_1 = \{\mathcal{D}_1\}$ and $\mathcal{D}_1$ is G.A.S using Lyapunov–LaSalle asymptotic stability theorem.

**Theorem 3** If $\mathcal{R}_2 > 1$, $\mathcal{R}_1/\mathcal{R}_2 \leq 1$ and $\mathcal{R}_4 \leq 1$, then $\mathcal{D}_2$ is G.A.S.

**Proof** Define $\Phi_2(S, L, I, E, Y, V, C\ell, C\gamma)$ as:

$$\Phi_2 = S_2 F\left(\frac{S}{S_2}\right) + \frac{\lambda}{\beta_\gamma + \lambda} L + \frac{\gamma + \lambda}{\beta_\gamma + \lambda} I + \frac{1}{\varphi} E_2 F\left(\frac{E}{E_2}\right) + \frac{\psi + \omega}{\varphi \psi} Y_2 F\left(\frac{Y}{Y_2}\right) + \frac{a(\gamma + \lambda)}{b(\beta_\gamma + \lambda)} V + \frac{\mu_1(\gamma + \lambda)}{\sigma_1(\beta_\gamma + \lambda)} C\ell + \frac{\mu_2(\psi + \omega)}{\varphi \psi \sigma_2} C\gamma.$$

We calculate $\frac{d\Phi_2}{dt}$ as:

$$\frac{d\Phi_2}{dt} = \left(1 - \frac{S_2}{S}\right) [\rho - \alpha S - \eta_1 SV - \eta_2 SY] + \frac{\lambda}{\beta_\gamma + \lambda} [(1 - \beta)\eta_1 SV - (\lambda + \gamma) L] + \frac{\gamma + \lambda}{\beta_\gamma + \lambda} [\beta \eta_1 SV + \lambda L - aI - \mu_1 C\ell I] + \frac{1}{\varphi} \left(1 - \frac{E_2}{E}\right) [\varphi \eta_2 SY + rY - (\psi + \omega) E] + \frac{\psi + \omega}{\varphi \psi} \left(1 - \frac{Y_2}{Y}\right) [\psi E - \delta Y - \mu_2 C\gamma Y] + \frac{a(\gamma + \lambda)}{b(\beta_\gamma + \lambda)} [bI - \epsilon V] + \frac{\mu_1(\gamma + \lambda)}{\sigma_1(\beta_\gamma + \lambda)} [\sigma_1 C\ell I - \pi_1 C\ell] + \frac{\mu_2(\psi + \omega)}{\varphi \psi \sigma_2} [\sigma_2 C\gamma Y - \pi_2 C\gamma] = \left(1 - \frac{S_2}{S}\right) (\rho - \alpha S) + \eta_1 S_2 V + \eta_2 S_2 Y + \frac{r}{\varphi} Y - \eta_2 SY \frac{E_2}{E} - \frac{r}{\varphi} Y \frac{E_2}{E} + \frac{\psi + \omega}{\varphi} E_2 - \frac{\delta(\psi + \omega)}{\varphi \psi} Y - \frac{\psi + \omega}{\varphi} Y \frac{E_2}{E} + \frac{\delta(\psi + \omega)}{\varphi \psi} Y_2 + \frac{\mu_2(\psi + \omega)}{\varphi \psi} Y_2 + \frac{\mu_2(\psi + \omega)}{\varphi \psi} C\gamma Y_2 - \frac{\mu_1(\pi_1(\gamma + \lambda)}{\sigma_1(\beta_\gamma + \lambda)} C\ell - \frac{\mu_2(\pi_2(\psi + \omega)}{\varphi \psi \sigma_2} C\gamma.$$

Using the equilibrium conditions for $\mathcal{D}_2$:

$$\rho = \alpha S_2 + \eta_2 S_2 Y_2, \quad \eta_2 S_2 Y_2 + \frac{r}{\varphi} Y_2 = \frac{\psi + \omega}{\varphi} E_2 = \frac{\delta(\psi + \omega)}{\varphi \psi} Y_2,$$

we obtain
\[
\frac{d\Phi_2}{dt} = \left(1 - \frac{S_2}{S}\right)(xS_2 - xS) + \eta_2S_2Y_2\left(1 - \frac{S_2}{S}\right)
\]
\[+
\eta_1S_2V - \eta_2S_2Y_2 \frac{SYE_2}{S_2Y_2E} - \frac{r}{\phi} Y_2 \frac{YE_2}{Y_2E}
\]
\[+
\eta_2S_2Y_2 + \frac{r}{\phi} Y_2 - \eta_2S_2Y_2 \frac{EY_2}{E_2Y} - \frac{r}{\phi} Y_2 \frac{EY_2}{E_2Y}
\]
\[+
\eta_2S_2Y_2 + \frac{r}{\phi} Y_2 + \frac{\mu_2(\psi + \omega)}{\phi}\sigma_2 Y_2
\]
\[-a(\gamma + \lambda)\frac{V}{S} - \mu_1\pi_1(\gamma + \lambda)\sigma_1(\beta\gamma + \lambda) C' - \frac{\mu_2\pi_2(\psi + \omega)}{\phi}\sigma_2 Y_2
\]
\[= -a\left(\frac{S - S_2}{S}\right)^2 + \frac{r}{\phi} \left(2 - \frac{YE_2}{Y_2E} - \frac{EY_2}{E_2Y}\right)
\]
\[+
\eta_2S_2Y_2\left(3 - \frac{S_2}{S} - \frac{SYE_2}{S_2Y_2E} - \frac{EY_2}{E_2Y}\right)
\]
\[+
\frac{a(\gamma + \lambda)}{b(\beta\gamma + \lambda)} \left(\frac{\eta_1S_2b(\beta\gamma + \lambda)}{a(\gamma + \lambda)} - 1\right) V - \frac{\mu_1\pi_1(\gamma + \lambda)}{\sigma_1(\beta\gamma + \lambda)} C'
\]
\[+
\frac{\mu_2\pi_2(\psi + \omega)}{\phi}\sigma_2 \left(\frac{\pi_2}{\pi_2} - 1\right) C'
\]
\[= -a\left(\frac{S - S_2}{S}\right)^2 - \frac{r}{\phi} \left(\frac{YE_2}{E_2Y}\right)^2 + \eta_2S_2Y_2\left(3 - \frac{S_2}{S} - \frac{SYE_2}{S_2Y_2E} - \frac{EY_2}{E_2Y}\right)
\]
\[+
\frac{a(\gamma + \lambda)}{b(\beta\gamma + \lambda)} (\mathcal{R}_1/\mathcal{R}_2 - 1) V - \frac{\mu_1\pi_1(\gamma + \lambda)}{\sigma_1(\beta\gamma + \lambda)} C'
\]
\[+
\frac{\mu_2(\psi + \omega)}{\phi}\sigma_2 \left(\frac{\pi_2}{\pi_2} + \frac{\eta_2\pi_2}{\eta_2}\right) (\mathcal{R}_4 - 1) C'.
\]

Thus, if \(\mathcal{R}_1/\mathcal{R}_2 \leq 1\) and \(\mathcal{R}_4 \leq 1\), then using inequality (15) we get \(\frac{d\Phi_2}{dt} \leq 0\) for all \(S, L, I, E, Y, V, C', C' > 0\). Moreover, \(\frac{d\Phi_2}{dt} = 0\) at \(S = S_2, E = E_2, Y = Y_2\) and \(V = C' = C' = 0\). The solutions of system (4) converge to \(Y'_2\) which contains elements with \(V = 0\), and then \(V = 0\). The sixth equation of system (4) implies
\[0 = \dot{V} = bI.\]

Thus, we get \(I(t) = 0\) for all \(t\). Moreover, we have \(\dot{I} = 0\). Thus, the third equation of system (4) gives
\[0 = \dot{I} = \lambda L,
\]
which yields \(L(t) = 0\) for all \(t\). Therefore, \(\tau'_2 = \{D_2\}\). By applying Lyapunov–LaSalle asymptotic stability theorem we get that \(D_2\) is G.A.S. \(\Box\)
Theorem 4  If $R_3 > 1$ and $R_5 \leq 1$, then $D_3$ is G.A.S.

Proof  Define a function $\Phi_3(S, L, E, Y, V, C', C')$ as:

$$
\Phi_3 = S_3 F\left(\frac{S}{S_3}\right) + \frac{\lambda}{\beta\gamma + \lambda} L_3 F\left(\frac{L}{L_3}\right) + \frac{\gamma + \lambda}{\beta\gamma + \lambda} I_3 F\left(\frac{I}{I_3}\right) + \frac{1}{\phi} E + \frac{\psi + \omega}{\phi\psi} Y
$$

$$
+ \frac{\eta_1 S_3}{\varepsilon} V_3 F\left(\frac{V}{V_3}\right) + \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\beta\gamma + \lambda)} C'_3 F\left(\frac{C'_3}{C'_3}\right) + \frac{\mu_2 (\psi + \omega)}{\phi\psi\sigma_2} C'^'.
$$

We calculate $\frac{d\Phi_3}{dt}$ as:

$$
\frac{d\Phi_3}{dt} = \left(1 - \frac{S_3}{S}\right) [\rho - \varepsilon S - \eta_1 SV - \eta_2 SY] + \frac{\lambda}{\beta\gamma + \lambda} \left(1 - \frac{L_3}{L}\right)
$$

$$
\times \left[(1 - \beta)\eta_1 SV - (\lambda + \gamma)L\right]
$$

$$
+ \frac{\gamma + \lambda}{\beta\gamma + \lambda} \left(1 - \frac{I_3}{I}\right) [\beta\eta_1 SV + \lambda L - aI - \mu_1 C' I]
$$

$$
+ \frac{1}{\phi} [\phi\eta_2 SY + rY - (\psi + \omega)E]
$$

$$
+ \frac{\psi + \omega}{\phi\psi} \left[\psi E - \delta Y - \mu_2 C'^' Y\right] + \frac{\eta_1 S_3}{\varepsilon} \left[1 - \frac{V_3}{V}\right] [bI - \varepsilon V]
$$

$$
+ \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\beta\gamma + \lambda)} \left(1 - \frac{C'_3}{C'}\right) [\sigma_1 C' I - \pi_1 C']
$$

$$
+ \frac{\mu_2 (\psi + \omega)}{\phi\psi\sigma_2} [\sigma_2 C'^' Y - \pi_2 C'^' ]
$$

$$
= \left(1 - \frac{S_3}{S}\right) [\rho - \varepsilon S + \eta_2 S_3 Y - \frac{\lambda(1 - \beta)}{\beta\gamma + \lambda} \eta_1 SV \frac{L_3}{L} + \frac{\lambda(\gamma + \lambda)}{\beta\gamma + \lambda} L_3
$$

$$
- \frac{a(\gamma + \lambda)}{\beta\gamma + \lambda} I - \frac{\beta(\gamma + \lambda)}{\beta\gamma + \lambda} \eta_1 SV \frac{I_3}{I} - \frac{\lambda(\gamma + \lambda)}{\beta\gamma + \lambda} L_3 \frac{I_3}{I} + \frac{a(\gamma + \lambda)}{\beta\gamma + \lambda} I_3
$$

$$
+ \frac{\mu_1 (\gamma + \lambda)}{\beta\gamma + \lambda} C'I_3 + \frac{r}{\phi} Y - \frac{\delta(\psi + \omega)}{\phi\psi} Y + \frac{\eta_1 S_3}{\varepsilon} bI
$$

$$
- \frac{\eta_1 S_3}{\varepsilon} bI \frac{V_3}{V} + \frac{\eta_1 S_3 V_3}{\varepsilon}
$$

$$
- \frac{\mu_1 \pi_1 (\gamma + \lambda)}{\sigma_1 (\beta\gamma + \lambda)} C' - \frac{\mu_1 (\gamma + \lambda)}{\beta\gamma + \lambda} \frac{C'_3 I}{C'_3} + \frac{\mu_1 \pi_1 (\gamma + \lambda)}{\sigma_1 (\beta\gamma + \lambda)} C'_3
$$

$$
- \frac{\mu_2 \pi_2 (\psi + \omega)}{\phi\psi\sigma_2} C'^'.
$$

Using the equilibrium conditions for $D_3$:}
\[ \rho = \alpha S_3 + \eta_1 S_3 V_3, \quad \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_3 V_3 = \frac{\lambda(\gamma + \lambda)}{\beta \gamma + \lambda} L_3, \]

\[ \eta_1 S_3 V_3 = \frac{a(\gamma + \lambda)}{\beta \gamma + \lambda} I_3 + \frac{\mu_1(\gamma + \lambda)}{\beta \gamma + \lambda} C_3 I_3, \]

\[ I_3 = \frac{\pi_1}{\sigma_1}, \quad V_3 = \frac{b}{\varepsilon} I_3 = \frac{b \pi_1}{\varepsilon \sigma_1}, \]

we obtain

\[ \frac{d\Phi_3}{dt} = \left( 1 - \frac{S_3}{S} \right) (\alpha S_3 - \alpha S) + \eta_1 S_3 V_3 \left( \frac{1 - S_3}{S} \right) + \left( \eta_2 S_3 - \frac{(\delta - r) \psi + \delta \omega}{\phi \psi} \right) Y - \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_3 V_3 \left( \frac{SVL_3}{S_3 V_3 L} + \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_3 V_3 - \frac{\beta(\gamma + \lambda)}{\beta \gamma + \lambda} \eta_1 S_3 V_3 \frac{SVI_3}{S_3 V_3 I} \right) \]

\[ = -\alpha \frac{(S - S_3)^2}{S} + \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_3 V_3 \left( \frac{4 - S_3}{S} - \frac{SVL_3}{S_3 V_3 I} - \frac{LI_3}{I_3 V} \right) + \frac{\beta(\gamma + \lambda)}{\beta \gamma + \lambda} \eta_1 S_3 V_3 \left( \frac{3 - S_3}{S} - \frac{SVI_3}{S_3 V_3 I} - \frac{IV_3}{I_3 V} \right) \]

\[ = -\alpha \frac{(S - S_3)^2}{S} + \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_3 V_3 \left( \frac{4 - S_3}{S} - \frac{SVL_3}{S_3 V_3 I} - \frac{LI_3}{I_3 V} \right) + \frac{\beta(\gamma + \lambda)}{\beta \gamma + \lambda} \eta_1 S_3 V_3 \left( \frac{3 - S_3}{S} - \frac{SVI_3}{S_3 V_3 I} - \frac{IV_3}{I_3 V} \right) \]

\[ \quad + \frac{\beta(\gamma + \lambda)}{\beta \gamma + \lambda} \eta_1 S_3 V_3 \left( \frac{3 - S_3}{S} - \frac{SVI_3}{S_3 V_3 I} - \frac{IV_3}{I_3 V} \right) \]

\[ = -\alpha \frac{(S - S_3)^2}{S} + \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_3 V_3 \left( \frac{4 - S_3}{S} - \frac{SVL_3}{S_3 V_3 I} - \frac{LI_3}{I_3 V} \right) + \frac{\beta(\gamma + \lambda)}{\beta \gamma + \lambda} \eta_1 S_3 V_3 \left( \frac{3 - S_3}{S} - \frac{SVI_3}{S_3 V_3 I} - \frac{IV_3}{I_3 V} \right) \]

\[ + \frac{\beta(\gamma + \lambda)}{\beta \gamma + \lambda} \eta_1 S_3 V_3 \left( \frac{3 - S_3}{S} - \frac{SVI_3}{S_3 V_3 I} - \frac{IV_3}{I_3 V} \right) \]

\[ + \frac{\mu_2 \pi_2(\psi + \omega)}{\phi \psi \sigma_2} \left( \Re_5 - 1 \right) Y \]

\[ - \frac{\mu_2 \pi_2(\psi + \omega)}{\phi \psi \sigma_2} C^\gamma. \]

Hence, if \( \Re_5 \leq 1 \), then using inequalities (13)–(14) we get \( \frac{d\Phi_1}{dt} \leq 0 \) for all \( S, L, I, E, Y, V, C', C^\gamma > 0 \). Moreover, \( \frac{d\Phi_3}{dt} = 0 \) at \( S = S_3, L = L_3, I = I_3, V = V_3 \) and \( Y = C^\gamma = 0 \). We note that the solutions of system (4) tend to \( Y'_3 \) which includes elements with \( S(t) = S_3, L(t) = L_3, I(t') = I_3, V(t) = V_3, Y(t) = 0 \), then \( \dot{I}(t) = 0, \dot{Y}(t) = 0 \) and from the third and fifth equations of system (4) we have

\[ 0 = \dot{I}(t) = \beta \eta_1 S_3 V_3 + \dot{\lambda} L_3 - \alpha L_3 - \mu_1 C(t) I_3, \]

\[ 0 = \dot{Y}(t) = \psi E(t), \]

which give \( C(t) = C'_3 \) and \( E(t) = 0 \) for all \( t \). Therefore, \( \gamma'_3 = \{ \sigma_3 \} \). Applying Lyapunov–LaSalle asymptotic stability theorem we get \( D_3 \) is G.A.S. \( \square \)

**Theorem 5** If \( \Re_4 > 1 \) and \( \Re_6 \leq 1 \), then \( D_3 \) is G.A.S.

**Proof** Define \( \Phi_4(S, L, I, E, Y, V, C', C^\gamma) \) as:
\[
\Phi_4 = S_4 F\left(\frac{S}{S_4}\right) + \frac{\lambda}{\beta_1 + \lambda} L + \frac{\gamma + \lambda}{\beta_1 + \lambda} I + \frac{1}{\varphi} E_4 F\left(\frac{E}{E_4}\right) + \frac{\psi + \omega}{\varphi \psi} Y_4 F\left(\frac{Y}{Y_4}\right) + \frac{\alpha(\gamma + \lambda)}{b(\beta_1 + \lambda)} V + \frac{\mu_1(\gamma + \lambda)}{\sigma_1(\beta_1 + \lambda)} C^I + \frac{\mu_2(\psi + \omega)}{\varphi \psi \sigma_2} C^Y_4 F\left(\frac{C^Y}{C^Y_4}\right).
\]

Calculating \(\frac{d\Phi_4}{dt}\) as:

\[
\frac{d\Phi_4}{dt} = \left(1 - \frac{S_4}{S}\right)\left[\rho - \alpha S - \eta_1 SV - \eta_2 SY\right] + \frac{\lambda}{\beta_1 + \lambda} \left[(1 - \beta)\eta_1 SV - (\lambda + \gamma) L\right] + \frac{\gamma + \lambda}{\beta_1 + \lambda} \left[\beta \eta_1 SV + \lambda L - a I - \mu_1 C^I\right] + \frac{1}{\varphi} \left(1 - \frac{E_4}{E}\right) \left[\varphi \eta_2 SY + r Y - (\psi + \omega) E\right] + \frac{\psi + \omega}{\varphi \psi} \left(1 - \frac{Y_4}{Y}\right) \left[\psi E - \delta Y - \mu_2 C^Y Y\right] + \frac{\alpha(\gamma + \lambda)}{b(\beta_1 + \lambda)} \left[\beta I - \varepsilon V\right] + \frac{\mu_1(\gamma + \lambda)}{\sigma_1(\beta_1 + \lambda)} C^I + \frac{\sigma_1 C^I I - \pi_1 C^I}{\sigma_1 C^I I - \pi_1 C^I} + \frac{\mu_2(\psi + \omega)}{\varphi \psi \sigma_2} \left(1 - \frac{C^Y_4}{C^Y}\right) \left[\sigma_2 C^Y Y - \pi_2 C^Y\right]
\]

\[
= \left(1 - \frac{S_4}{S}\right)\left[\rho - \alpha S + \eta_1 S_4 V + \eta_2 S_4 Y + \frac{r}{\varphi} Y - \eta_2 SY \frac{E_4}{E}\right] - \frac{r}{\varphi} Y \frac{E_4}{E} + \frac{\psi + \omega}{\varphi} E_4
\]

\[
- \frac{\delta(\psi + \omega)}{\varphi \psi} Y - \frac{\psi + \omega}{\varphi} E_4 \frac{Y_4}{Y} + \frac{\delta(\psi + \omega)}{\varphi \psi} Y_4
\]

\[
+ \frac{\mu_2(\psi + \omega)}{\varphi \psi} C^Y Y_4 - \frac{\alpha(\gamma + \lambda)}{b(\beta_1 + \lambda)} V
\]

\[
- \frac{\mu_1(\gamma + \lambda)}{\sigma_1(\beta_1 + \lambda)} C^I + \frac{\mu_2(\psi + \omega)}{\varphi \psi \sigma_2} C^Y
\]

\[
- \frac{\mu_2(\psi + \omega)}{\varphi \psi} C^I Y + \frac{\mu_2(\psi + \omega)}{\varphi \psi \sigma_2} C^Y.
\]

Using the equilibrium conditions for \(D_4\):

\[
\rho = \alpha S_4 + \eta_2 S_4 Y_4, \quad Y_4 = \frac{\pi_2}{\sigma_2},
\]

\[
\eta_2 S_4 Y_4 + \frac{r}{\varphi} Y_4 = \frac{\psi + \omega}{\varphi} E_4 = \frac{\delta(\psi + \omega)}{\varphi \psi} Y_4 + \frac{\mu_2(\psi + \omega)}{\varphi \psi} C^Y_4 Y_4.
\]

We obtain
\[
\frac{d\Phi_4}{dt} = \left(1 - \frac{S_4}{S}\right)(zS_4 - zS) + \eta_2S_4Y_4\left(1 - \frac{S_4}{S}\right) + \eta_1S_4V - \eta_2S_4Y_4\frac{SY_4}{S_4Y_4E}
\]
\[
- \frac{r}{\phi}Y_4\frac{YE_4}{E_4E} + \eta_2S_4Y_4 + \frac{r}{\phi}Y_4 - \eta_2S_4Y_4\frac{EY_4}{E_4Y} - \frac{r}{\phi}Y_4\frac{EY_4}{E_4Y}
\]
\[
+ \eta_2S_4Y_4 + \frac{a\varepsilon(\gamma + \lambda)}{b(\beta\gamma + \lambda)}V - \frac{\mu_1\pi_1(\gamma + \lambda)}{\sigma_1(\beta\gamma + \lambda)}C^t
\]
\[
= -a\frac{(S - S_4)^2}{S} + \eta_2S_4Y_4\left(3 - \frac{SY_4}{S_4Y_4E} - \frac{EY_4}{E_4Y}\right)
\]
\[
+ \frac{r}{\phi}Y_4\left(2 - \frac{YE_4}{E_4E} - \frac{EY_4}{E_4Y}\right)
\]
\[
+ \frac{a\varepsilon(\gamma + \lambda)}{b(\beta\gamma + \lambda)}\left(\eta_1b(\beta\gamma + \lambda)S_4 - \frac{a\varepsilon(\gamma + \lambda)}{a\varepsilon(\gamma + \lambda)} - 1\right)V - \frac{\mu_1\pi_1(\gamma + \lambda)}{\sigma_1(\beta\gamma + \lambda)}C^t
\]
\[
= -a\frac{(S - S_4)^2}{S} - \frac{r}{\phi}\left(\frac{YE_4 - EY_4}{EE_4Y}\right) + \eta_2S_4Y_4\left(3 - \frac{SY_4}{S_4Y_4E} - \frac{EY_4}{E_4Y}\right)
\]
\[
+ \frac{a\varepsilon(\gamma + \lambda)}{b(\beta\gamma + \lambda)}(9R_6 - 1)V - \frac{\mu_1\pi_1(\gamma + \lambda)}{\sigma_1(\beta\gamma + \lambda)}C^t.
\]

Hence, if \( R_6 \leq 1 \), then using inequality (15) we get \( \frac{d\Phi_6}{dt} \leq 0 \) for all \( S, L, E, Y, V, C^t, C^v > 0 \). In addition, we have \( \frac{d\Phi_6}{dt} = 0 \) at \( S = S_4, E = E_4, Y = Y_4 \) and \( V = C^t = 0 \). The trajectories of system (4) converge to \( Y_4^* \) which includes elements with \( E = E_4, Y = Y_4, V = 0 \), and then \( \dot{Y} = \dot{V} = 0 \). The fifth and sixth equations of system (4) imply
\[
0 = \dot{Y} = \psi E_4 - \delta Y_4 - \mu_2 C^v Y_4,
\]
\[
0 = \dot{V} = bI,
\]
which give \( C^v(t) = C^v_4 \) and \( I(t) = 0 \) for all \( t \). Moreover, we have \( \dot{I} = 0 \), then from the third equation of system (4) we get
\[
0 = \dot{I} = \lambda L,
\]
which yields \( L(t) = 0 \) for all \( t \). Therefore, \( \mathcal{R}'_4 = \{D_4\} \). By applying Lyapunov–LaSalle asymptotic stability theorem we get that \( D_4 \) is G.A.S.

**Theorem 6** If \( R_5 > 1, R_8 \leq 1 \) and \( R_1/R_2 > 1 \), then \( D_5 \) is G.A.S.

**Proof** Define \( \Phi_5(S, L, E, Y, V, C^t, C^v) \) as:
\[
\Phi_5 = S_5F\left(\frac{S}{S_5}\right) + \frac{\lambda}{\beta\gamma + \lambda}L_5F\left(\frac{L}{L_5}\right) + \frac{\gamma + \lambda}{\beta\gamma + \lambda}I_5F\left(\frac{I}{I_5}\right)
\]
\[
+ \frac{1}{\phi}E_5F\left(\frac{E}{E_5}\right) + \frac{\psi + \omega}{\phi\psi}Y_5F\left(\frac{Y}{Y_5}\right)
\]
\[
+ \frac{\eta_1S_5}{\varepsilon}V_5F\left(\frac{V}{V_5}\right) + \frac{\mu_1(\gamma + \lambda)}{\sigma_1(\beta\gamma + \lambda)}C^t_5F\left(\frac{C^t}{C^t_5}\right) + \frac{\mu_2(\psi + \omega)}{\phi\psi\sigma_2}C^v.
\]
Calculating $\frac{d\Phi_5}{dt}$ as:

$$
\frac{d\Phi_5}{dt} = \left(1 - \frac{S_5}{S}\right)[\rho - \alpha S - \eta_1 SV - \eta_2 SY] + \frac{\lambda}{\beta_\gamma + \lambda}\left(1 - \frac{L_5}{L}\right) \\
\times \left[(1 - \beta)\eta_1 SV - (\lambda + \gamma)L\right] \\
+ \frac{\gamma + \lambda}{\beta_\gamma + \lambda}\left(1 - \frac{I_5}{I}\right)[\beta_\gamma \eta_1 SV + \lambda L - a I - \mu_1 C^l I] \\
+ \frac{1}{\phi}\left(1 - \frac{E_5}{E}\right)[\phi \eta_2 SY + r Y - (\psi + \omega)E] \\
+ \frac{\psi + \omega}{\phi \psi}\left(1 - \frac{Y_5}{Y}\right)[\psi E - \delta Y - \mu_2 C^Y Y] + \frac{\eta_1 S_5}{\varepsilon}\left(1 - \frac{V_5}{V}\right)[b I - e V] \\
+ \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\beta_\gamma + \lambda)}\left(1 - \frac{C^l_5}{C^l}\right)[\sigma_1 C^l I - \pi_1 C^l] \\
+ \frac{\mu_2 (\psi + \omega)}{\phi \psi \sigma_2}[\sigma_2 C^Y Y - \pi_2 C^Y] \\
= \left(1 - \frac{S_5}{S}\right)(\rho - \alpha S) + \eta_2 S_5 Y - \frac{\lambda (1 - \beta)}{\beta_\gamma + \lambda} \eta_1 SV \frac{L_5}{L} \\
+ \frac{\lambda (\gamma + \lambda)}{\beta_\gamma + \lambda} L_5 - \frac{a (\gamma + \lambda)}{\beta_\gamma + \lambda} I \\
- \frac{\beta (\gamma + \lambda)}{\beta_\gamma + \lambda} \eta_1 SV \frac{I_5}{I} - \frac{\lambda (\gamma + \lambda)}{\beta_\gamma + \lambda} L \frac{I_5}{I} \\
+ \frac{a (\gamma + \lambda)}{\beta_\gamma + \lambda} I_5 + \frac{\mu_1 (\gamma + \lambda)}{\beta_\gamma + \lambda} C^l I_5 + \frac{r}{\phi} Y \\
- \eta_2 SY \frac{E_5}{E} - \frac{r}{\phi} Y \frac{E_5}{E} + \frac{\psi + \omega}{\phi} E_5 - \frac{\delta (\psi + \omega)}{\phi \psi} Y \\
- \frac{\psi + \omega}{\phi} E \frac{Y_5}{Y} + \frac{\delta (\psi + \omega)}{\phi \psi} Y_5 \\
+ \frac{\mu_2 (\psi + \omega)}{\phi \psi} C^Y Y_5 + \eta_1 S_5 \frac{b I}{\varepsilon} - \eta_1 S_5 V_5 \frac{b I}{\varepsilon V} \\
+ \eta_1 S_5 V_5 - \frac{\mu_1 \pi_1 (\gamma + \lambda)}{\sigma_1 (\beta_\gamma + \lambda)} C^l \\
- \frac{\mu_1 (\gamma + \lambda)}{\beta_\gamma + \lambda} C^l_5 + \frac{\mu_1 \pi_1 (\gamma + \lambda)}{\sigma_1 (\beta_\gamma + \lambda)} C^l_5 - \frac{\mu_2 \pi_2 (\psi + \omega)}{\phi \psi \sigma_2} C^Y.
$$

Using the equilibrium conditions for $D_5$:
\[ \rho = \alpha S_5 + \eta_1 S_5 V_5 + \eta_2 S_5 Y_5, \quad \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_5 V_5 = \frac{\lambda(\gamma + \lambda)}{\beta \gamma + \lambda} L_5, \]

\[ \eta_1 S_5 V_5 = \frac{a(\gamma + \lambda)}{\beta \gamma + \lambda} I_5 + \mu_1(\gamma + \lambda) C_5^1 I_5, \]

\[ \eta_2 S_3 Y_5 + \frac{r}{\varphi} Y_5 = \frac{\psi + \omega}{\varphi} E_5 = \frac{\delta(\psi + \omega)}{\varphi \psi} Y_5, \]

\[ I_5 = \frac{\pi_1}{\sigma_1}, \quad V_5 = \frac{b I_5}{\varepsilon}. \]

We obtain

\[
\frac{d\Phi_5}{dr} = \left( 1 - \frac{S_5}{S} \right) (\alpha S_5 - \alpha S) + (\eta_1 S_5 V_5 + \eta_2 S_5 Y_5) \left( 1 - \frac{S_5}{S} \right)
- \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_5 V_5 \frac{SVL_5}{S_5 V_5 L}
+ \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_5 V_5 - \frac{\beta(\gamma + \lambda)}{\beta \gamma + \lambda} \eta_1 S_5 V_5 \frac{SVI_5}{S_5 V_5 I}
- \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_5 V_5 \frac{L_5}{L_5 I} + \eta_1 S_5 V_5
- \eta_2 S_5 Y_5 \frac{SYE_5}{S_5 Y_5 E} - \frac{r}{\varphi} Y_5 \frac{YE_5}{Y_5 E} + \eta_2 S_5 Y_5 + \frac{r}{\varphi} Y_5
- \eta_2 S_5 Y_5 \frac{EY_5}{E_5 Y} - \frac{r}{\varphi} Y_5 \frac{EY_5}{E_5 Y}
+ \eta_2 S_5 Y_5 + \frac{r}{\varphi} Y_5 - \eta_1 S_5 V_5 \frac{IV_5}{I_5 V} + \eta_1 S_5 V_5
+ \frac{\mu_2 \pi_2 (\psi + \omega)}{\varphi \psi \sigma_2} \left( \frac{\sigma_2 Y_5}{\pi_2} - 1 \right) C^\gamma
= -\alpha \left( S_5 - S \right)^2 \left( 1 - \frac{S_5}{S} \right) - \frac{r}{\varphi} \left( \frac{YE_5}{E_5 Y} - \frac{YE_5}{E_5 Y} \right)^2 + \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_5 V_5
\times \left( 4 - \frac{S_5}{S} - \frac{SVL_5}{S_5 V_5 L} - \frac{L_5}{L_5 I} - \frac{IV_5}{I_5 V} \right)
+ \frac{\beta(\gamma + \lambda)}{\beta \gamma + \lambda} \eta_1 S_5 V_5 \left( 3 - \frac{S_5}{S} - \frac{SVI_5}{S_5 V_5 I} - \frac{IV_5}{I_5 V} \right)
+ \eta_2 S_5 Y_5 \left( 3 - \frac{S_5}{S} - \frac{SYE_5}{S_5 Y_5 E} - \frac{EY_5}{E_5 Y} \right)
+ \frac{\mu_2 \pi_2 (\psi + \omega)}{\varphi \psi \sigma_2} \left( \frac{\sigma_2 Y_5}{\pi_2} - 1 \right) C^\gamma. \tag{20} \]
Then, Eq. (20) will be reduced to the form

\[
\frac{d\Phi_5}{dt} = -\alpha \left( \frac{S - S_5}{S} \right)^2 \frac{r}{E} \left( \frac{Y E_5 - E Y_5}{E} \right)^2 + \frac{\lambda (1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_5 V_5 \\
\times \left( 4 - \frac{S_5}{S} \frac{S V L_5}{S_5 V_5 L} - \frac{L I_5}{L_5 I} - \frac{I V_5}{I_5 V} \right) \\
+ \frac{\beta (\gamma + \lambda)}{\beta \gamma + \lambda} \eta_1 S_5 V_5 \left( 3 - \frac{S_5}{S} \frac{S V I_5}{S_5 V I} - \frac{I V_5}{I_5 V} \right) \\
+ \eta_2 S_5 Y_5 \left( 3 - \frac{S_5}{S} \frac{S Y E_5}{S Y_5 E} - \frac{E Y_5}{E_5 Y} \right) \\
+ \frac{\mu_2 (\psi + \omega) (\pi_1 \eta_1 b \sigma_2 + \pi_2 \eta_2 \sigma_1 \sigma_1 + \chi \sigma_1 \sigma_2)}{\phi \psi \eta_2 \sigma_1 \sigma_2} \left( 1 - \frac{\mathcal{R}_8}{C^\gamma} \right).
\]

Hence, if \( \mathcal{R}_8 \leq 1 \), then using inequalities (13)-(15) we get \( \frac{d\Phi_5}{dt} \leq 0 \) for all \( S, L, I, E, Y, V, C^\gamma, C^\gamma > 0 \). Further, \( \frac{d\Phi_5}{dt} = 0 \) when \( S = S_5, L = L_5, I = I_5, E = E_5, Y = Y_5, V = V_5 \) and \( C^\gamma = 0 \). The solutions of system (4) converge to \( \tilde{Y} \), which includes elements with \( S = S_5, L = L_5, I = I_5, V = V_5 \), and then \( \tilde{I} = 0 \). The third equation of system (4) implies

\[
0 = \tilde{I} = \beta \eta_1 S_5 V_5 + \lambda L_5 - a L_5 - \mu_1 C^\gamma I_5,
\]

which yields \( C^\gamma(t) = C^\gamma_5 \) for all \( t \). Therefore, \( \gamma' = \{D_5\} \). By applying Lyapunov–LaSalle asymptotic stability theorem we get \( D_5 \) is G.A.S.

**Theorem 7** If \( \mathcal{R}_6 > 1, \mathcal{R}_7 \leq 1 \) and \( \mathcal{R}_2/\mathcal{R}_1 > 1 \), then \( D_6 \) is G.A.S.

**Proof** Define \( \Phi_6(S, L, I, E, Y, V, C^\gamma, C^\gamma) \) as:

\[
\Phi_6 = S_6 F \left( \frac{S}{S_6} \right) + \frac{\lambda}{\beta \gamma + \lambda} L_6 F \left( \frac{L}{L_6} \right) + \frac{\gamma + \lambda}{\beta \gamma + \lambda} I_6 F \left( \frac{I}{I_6} \right) \\
+ \frac{1}{\phi} E_6 F \left( \frac{E}{E_6} \right) + \frac{\psi + \omega}{\phi \psi} Y_6 F \left( \frac{Y}{Y_6} \right) \\
+ \frac{\eta_1 S_6}{\sigma} V_6 F \left( \frac{V}{V_6} \right) + \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\beta \gamma + \lambda)} C^\gamma + \frac{\mu_2 (\psi + \omega)}{\phi \psi \sigma_2} C_6^\gamma \frac{F \left( \frac{C^\gamma}{C_6^\gamma} \right)}{C^\gamma}.
\]

Calculating \( \frac{d\Phi_6}{dt} \) as:
\[
\frac{d\Phi_6}{dt} = \left(1 - \frac{S_6}{S}\right) \left[\rho - \pi S - \eta_1 SV - \eta_2 SY\right] \\
+ \frac{\lambda}{\beta_\gamma + \lambda} \left(1 - \frac{L_6}{L}\right) \left[(1 - \beta)\eta_1 SV - (\lambda + \gamma)L\right] \\
+ \frac{\gamma + \lambda}{\beta_\gamma + \lambda} \left(1 - \frac{I_6}{I}\right) \left[\beta\eta_1 SV + \lambda L - aI - \mu_1 C^I\right] \\
+ \frac{1}{\varphi} \left(1 - \frac{E_6}{E}\right) [\varphi\eta_2 SY + rY - (\psi + \omega)E] \\
+ \frac{\psi + \omega}{\varphi\psi} \left(1 - \frac{Y_6}{Y}\right) \left[\psi E - \delta Y - \mu_2 C^Y Y\right] \\
+ \frac{\eta_1 S_6}{\epsilon} \left(1 - \frac{V_6}{V}\right) \left[bI - \varepsilon V\right] \\
+ \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\beta_\gamma + \lambda)} \left[\sigma_1 C^I - \pi_1 C^I\right] \\
+ \frac{\mu_2 (\psi + \omega)}{\varphi\psi\sigma_2} \left(1 - \frac{C_6^Y}{C^Y}\right) \left[\sigma_2 C^Y Y - \pi_2 C^Y\right] \\
= \left(1 - \frac{S_6}{S}\right) \left[\rho - \pi S\right] + \frac{\lambda(1 - \beta)}{\beta_\gamma + \lambda} \eta_1 SV \frac{L_6}{L} \\
+ \frac{\lambda(\gamma + \lambda)}{\beta_\gamma + \lambda} L_6 - \frac{a(\gamma + \lambda)}{\beta_\gamma + \lambda} I \\
- \frac{\beta(\gamma + \lambda)}{\beta_\gamma + \lambda} \eta_1 SV \frac{I_6}{I} - \frac{\lambda(\gamma + \lambda)}{\beta_\gamma + \lambda} L_6 + \frac{a(\gamma + \lambda)}{\beta_\gamma + \lambda} I_6 \\
+ \frac{\mu_1 (\gamma + \lambda)}{\beta_\gamma + \lambda} C^I I_6 + \frac{r}{\varphi} Y \\
- \eta_2 SY \frac{E_6}{E} - \frac{r}{\varphi} Y \frac{E_6}{E} + \frac{\psi + \omega}{\varphi} \frac{E_6}{E} - \frac{\delta(\psi + \omega)}{\varphi\psi} Y \\
- \frac{\psi + \omega}{\varphi} \frac{Y_6}{Y} + \frac{\delta(\psi + \omega)}{\varphi\psi} Y_6 \\
+ \frac{\mu_2 (\psi + \omega)}{\varphi\psi\sigma_2} C^Y Y_6 + \eta_1 S_6 \frac{bI}{\epsilon} - \eta_1 S_6 V_6 \frac{bI}{\varepsilon V} + \eta_1 S_6 V_6 \\
- \frac{\mu_1 \pi_1 (\gamma + \lambda)}{\sigma_1 (\beta_\gamma + \lambda)} C^I \\
- \frac{\mu_2 \pi_2 (\psi + \omega)}{\varphi\psi\sigma_2} C^Y - \frac{\mu_2 (\psi + \omega)}{\varphi\psi} C_6^Y + \frac{\mu_2 \pi_2 (\psi + \omega)}{\varphi\psi\sigma_2} C_6^Y.
\]

Using the equilibrium conditions for \(D_6\):
\[
\rho = \alpha S_6 + \eta_1 S_6 V_6 + \eta_2 S_6 Y_6, \quad \eta_1 S_6 V_6 = \frac{a(\gamma + \lambda)}{\beta \gamma + \lambda} I_6,
\]

\[
\frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_6 V_6 = \frac{\lambda(\gamma + \lambda)}{\beta \gamma + \lambda} I_6
\]

\[
\eta_2 S_6 Y_6 + \frac{r}{\psi} Y_6 = \frac{\psi + \omega}{\phi} E_6 = \frac{\delta(\psi + \omega)}{\phi \psi} Y_6 + \frac{\mu_2(\psi + \omega)}{\phi \psi} C_t^t Y_6,
\]

\[
Y_6 = \frac{\pi_2}{\sigma_2}, \quad V_6 = \frac{b I_6}{\varepsilon}.
\]

We obtain
\[
\frac{d\Phi_6}{dr} = \left(1 - \frac{S_6}{S}\right) (\alpha S_6 - \alpha S) + (\eta_1 S_6 V_6 + \eta_2 S_6 Y_6) \left(1 - \frac{S_6}{S}\right)
\]

\[
- \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_6 V_6 S V L_6 + \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_6 V_6 S V I_6
\]

\[
- \eta_2 S_6 Y_6 \frac{S Y E_6}{S V_6 E} - \frac{r}{\psi} Y_6 \frac{Y E_6}{S V_6 Y_6} + \eta_2 S_6 Y_6 + \frac{r}{\psi} Y_6 - \eta_2 S_6 Y_6 \frac{E Y_6}{E_6 Y} - \frac{r}{\psi} Y_6 \frac{E Y_6}{E_6 Y}
\]

\[
+ \eta_2 S_6 Y_6 + \frac{r}{\psi} Y_6 - \eta_1 S_6 V_6 \frac{I V_6}{I_6 V} + \eta_1 S_6 V_6 + \frac{\mu_1 \pi_1 (\gamma + \lambda)}{\pi_1} \left(\frac{\sigma_1 I_6}{\pi_1} - 1\right) C^t
\]

\[
= -\frac{\chi(S - S_6)^2}{S} + \frac{\chi(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_6 V_6 \left(4 - \frac{S_6}{S}\right) \frac{S V L_6}{S V_6 V_6} - \frac{L L_6}{I_6 V} + \frac{I V_6}{I_6 V}
\]

\[
+ \frac{\beta(\gamma + \lambda)}{\beta \gamma + \lambda} \eta_1 S_6 V_6 \left(3 - \frac{S_6}{S}\right) - \frac{S V I_6}{S V_6 I_6 V}
\]

\[
+ \eta_2 S_6 Y_6 \left(3 - \frac{S_6}{S}\right) - \frac{S Y E_6}{S V_6 Y_6} - \frac{E Y_6}{E_6 Y}
\]

\[
+ \frac{r}{\psi} Y_6 \left(2 - \frac{Y E_6}{Y_6 E} - \frac{E Y_6}{E_6 Y}\right) + \frac{\mu_1 \pi_1 (\gamma + \lambda)}{\pi_1} \left(\frac{\sigma_1 I_6}{\pi_1} - 1\right) C^t.
\]

Then, Eq. (21) will be reduced to the form
\[
\frac{d\Phi_6}{dr} = -\frac{\chi(S - S_6)^2}{S} - \frac{r}{\psi} \left(\frac{Y E_6 - E Y_6}{Y E_6}\right)^2 + \frac{\chi(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_6 V_6
\]

\[
\times \left(4 - \frac{S_6}{S}\right) \frac{S V L_6}{S V_6 V_6} - \frac{L L_6}{I_6 V} + \frac{I V_6}{I_6 V}
\]

\[
+ \frac{\beta(\gamma + \lambda)}{\beta \gamma + \lambda} \eta_1 S_6 V_6 \left(3 - \frac{S_6}{S}\right) - \frac{S V I_6}{S V_6 I_6 V}
\]

\[
+ \eta_2 S_6 Y_6 \left(3 - \frac{S_6}{S}\right) - \frac{S Y E_6}{S V_6 Y_6} - \frac{E Y_6}{E_6 Y}
\]

\[
+ \frac{\mu_1 \pi_1 (\gamma + \lambda)(\pi_1 I_6 b \sigma_3 + \pi_2 I_6 \sigma_1 + \alpha \sigma_1 \sigma_2)}{\eta_1 b \sigma_1 \sigma_2 (\beta \gamma + \lambda)} (\mathcal{R}_7 - 1) C^t.
\]

Hence, if \(\mathcal{R}_7 \leq 1\), then using inequalities (13)–(15) we get \(\frac{d\Phi_6}{dr} \leq 0\) for all
$S, L, I, E, Y, V, C^l, C^V > 0$, where $\frac{dI_6}{dt} = 0$ occurs at $S = S_6$, $L = L_6$, $I = I_6$, $E = E_6$, $Y = Y_6$, $V = V_6$ and $C^l = 0$. The solutions of system (4) converge to $\mathcal{Y}_6$ which contains elements with $E = E_6$, $Y = Y_6$, and then $\dot{Y} = 0$. The fifth equation of system (4) implies

$$0 = \dot{Y} = \psi E_6 - \delta Y_6 - \mu_2 C^V Y_6,$$

which yields $C^V(t) = C^V_6$ for all $t$. Therefore, $\mathcal{Y}_6 = \{D_6\}$ and then by applying Lyapunov–LaSalle asymptotic stability theorem we get that $D_6$ is G.A.S. \hfill \square

**Theorem 8** If $R_7 > 1$ and $R_8 > 1$, then $D_7$ is G.A.S.

**Proof** Define $\Phi_7(S, L, I, E, Y, V, C^l, C^V)$ as:

$$\Phi_7 = S_7 F\left(\frac{S}{S_7}\right) + \frac{\lambda}{\beta_7 + \lambda} L_7 F\left(\frac{L}{L_7}\right) + \frac{\gamma + \lambda}{\beta_7 + \lambda} I_7 F\left(\frac{I}{I_7}\right) + \frac{1}{\varphi} E_7 F\left(\frac{E}{E_7}\right) + \frac{\psi + \omega}{\varphi \psi} Y_7 F\left(\frac{Y}{Y_7}\right) + \frac{\eta_1 S_7}{\varepsilon} V_7 F\left(\frac{V}{V_7}\right) + \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\beta_7 + \lambda)} C^l_7 F\left(\frac{C^l}{C^l_7}\right) + \frac{\mu_2 (\psi + \omega)}{\varphi \psi \sigma_2} C^V_7 F\left(\frac{C^V}{C^V_7}\right).$$

Calculating $\frac{d\Phi_7}{dt}$ as:

$$\frac{d\Phi_7}{dt} = \left(1 - \frac{S_7}{S}\right) \left[\rho - \alpha S - \eta_1 SV - \eta_2 SY\right] + \frac{\lambda}{\beta_7 + \lambda} \left(1 - \frac{L_7}{L}\right) [\beta \eta_1 SV + \lambda L - aI - \mu_1 C^l I]\]

$$+ \frac{1}{\varphi} \left(1 - \frac{E_7}{E}\right) [\varphi \eta_2 SY + rY - (\psi + \omega)E]\]

$$+ \frac{\psi + \omega}{\varphi \psi} \left(1 - \frac{Y_7}{Y}\right) [\psi E - \delta Y - \mu_2 C^V Y]\]

$$+ \frac{\eta_1 S_7}{\varepsilon} \left(1 - \frac{V_7}{V}\right) [bI - \varepsilon V]\]

$$+ \frac{\mu_1 (\gamma + \lambda)}{\sigma_1 (\beta_7 + \lambda)} \left(1 - \frac{C^l_7}{C^l}\right) [\sigma_1 C^l I - \pi_1 C^l]\]

$$+ \frac{\mu_2 (\psi + \omega)}{\varphi \psi \sigma_2} \left(1 - \frac{C^V_7}{C^V}\right) [\sigma_2 C^V Y - \pi_2 C^V]\]

$$= \left(1 - \frac{S_7}{S}\right) (\rho - \alpha S) + \eta_2 S_7 Y - \frac{\lambda (1 - \beta)}{\beta_7 + \lambda} \eta_1 S V L_7 / L.$$
\[ + \frac{\lambda(\gamma + \lambda)}{\beta \gamma + \lambda} L_I - \frac{a(\gamma + \lambda)}{\beta \gamma + \lambda} I \]
\[ - \frac{\beta(\gamma + \lambda)}{\beta \gamma + \lambda} \eta_1 SV_I I - \frac{\lambda(\gamma + \lambda)}{\beta \gamma + \lambda} L_I I + \frac{a(\gamma + \lambda)}{\beta \gamma + \lambda} I \]
\[ + \frac{\mu_1(\gamma + \lambda)}{\beta \gamma + \lambda} C_I I + \frac{r}{\varphi} Y \]
\[ - \eta_2 SY \frac{E_I}{E} - \frac{r}{\varphi} \frac{Y_I}{E} \psi + \omega \frac{E_I}{\varphi} Y_I - \frac{\delta(\psi + \omega)}{\varphi \psi} Y \]
\[ - \psi + \omega \frac{E_I}{\varphi} Y_I + \frac{\delta(\psi + \omega)}{\varphi \psi} Y_I \]
\[ + \frac{\mu_2(\psi + \omega)}{\varphi \psi} C_Y Y_I + \frac{\mu_1(\gamma + \lambda)}{\sigma_1(\beta \gamma + \lambda)} C^I \]
\[ - \frac{\mu_1(\gamma + \lambda)}{\beta \gamma + \lambda} C_I I + \frac{\mu_1(\gamma + \lambda)}{\sigma_1(\beta \gamma + \lambda)} C_I I - \frac{\mu_2(\psi + \omega)}{\varphi \psi \sigma_2} C_Y \]
\[ - \frac{\mu_2(\psi + \omega)}{\varphi \psi \sigma_2} C^I \]

Using the equilibrium conditions for \( D_I \):

\[ \rho = aS_I + \eta_1 S_I V_I + \eta_2 S_I Y_I, \quad \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_I V_I = \frac{\lambda(\gamma + \lambda)}{\beta \gamma + \lambda} L_I, \]
\[ \eta_1 S_I V_I = \frac{a(\gamma + \lambda)}{\beta \gamma + \lambda} I_I + \frac{\mu_1(\gamma + \lambda)}{\beta \gamma + \lambda} C_I I_I, \]
\[ \eta_2 S_I Y_I + \frac{r}{\varphi} Y_I = \frac{\psi + \omega}{\varphi} E_I = \frac{\delta(\psi + \omega)}{\varphi \psi} Y_I + \frac{\mu_2(\psi + \omega)}{\varphi \psi \sigma_2} C^I Y_I, \]
\[ Y_I = \frac{\pi_1}{\sigma_1}, \quad Y_I = \frac{\pi_2}{\sigma_2}, \quad V_I = \frac{b I_I}{\varepsilon}. \]

We obtain

\[ \frac{d \Phi_I}{dt} = \left( 1 - \frac{S_I}{S} \right) (aS_I - aS) + (\eta_1 S_I V_I + \eta_2 S_I Y_I) \left( 1 - \frac{S_I}{S} \right) \]
\[ - \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_I V_I SVL_I \]
\[ + \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_I V_I - \beta(\gamma + \lambda) \eta_1 S_I V_I SVL_I \]
\[ - \frac{\lambda(1 - \beta)}{\beta \gamma + \lambda} \eta_1 S_I V_I \frac{L_I}{L_I} + \eta_1 S_I V_I \]
\begin{align*}
- \eta_2 S_7 Y_7 \frac{SYE_7}{S_7 Y_7} - \frac{r}{\phi} Y_7 \frac{YE_7}{Y_7 E} + \eta_2 S_7 Y_7 + \frac{r}{\phi} Y_7 \\
- \eta_2 S_7 Y_7 \frac{EY_7}{E_7 Y} - \frac{r}{\phi} Y_7 \frac{EY_7}{E_7 Y} \\
+ \eta_2 S_7 Y_7 + \frac{r}{\phi} Y_7 - \eta_1 S_7 V_7 \frac{IV_7}{I_7 V} + \eta_1 S_7 V_7 \\
= -\alpha \frac{(S - S_7)^2}{S} - \frac{r}{\phi} \left( \frac{YE_7 - EY_7}{EE_7 Y} \right) + \frac{\lambda (1 - \beta)}{\beta_7 + \lambda} \eta_1 S_7 V_7 \\
\times \left( 4 - \frac{S_7}{S} - \frac{SVI_7}{S_7 V_7 L} - \frac{LI_7}{L_7 I} - \frac{IV_7}{I_7 V} \right) \\
+ \frac{\beta (\gamma + \lambda)}{\beta_7 + \lambda} \eta_1 S_7 V_7 \left( 3 - \frac{S_7}{S} - \frac{SYE_7}{S_7 Y_7 E} - \frac{EY_7}{E_7 Y} \right)
\end{align*}

Then using inequalities (13)-(15) we get \( \frac{d\Phi}{dt} \leq 0 \) for all \( S, L, I, E, Y, V, C^I, C^Y > 0 \). Further, \( \frac{d\Phi}{dt} = 0 \) when \( S = S_7, L = L_7, I = I_7, E = E_7, Y = Y_7 \) and \( V = V_7 \). The solutions of system (4) lead to \( \mathcal{Y}_7 \) which includes elements with \( S = S_7, L = L_7, I = I_7, E = E_7, Y = Y_7 \) and \( V = V_7 \), and then \( \dot{I} = \dot{Y} = 0 \). The third and fifth equations of system (4) imply

\[
0 = \dot{I} = \beta \eta_1 S_7 V_7 + \lambda L_7 - a I_7 - \mu_1 C^I I_7,
\]

\[
0 = \dot{Y} = \psi E_7 - \delta Y_7 - \mu_2 C^Y Y_7,
\]

which ensure that \( C^I(t) = C^I_7 \) and \( C^Y(t) = C^Y_7 \) for all \( t \). Thus \( \mathcal{X}_7 = \{ \mathcal{D}_7 \} \) and by applying Lyapunov–LaSalle asymptotic stability theorem we get that \( \mathcal{D}_7 \) is G.A.S. 

In Table 3, we summarize the global stability results given in Theorems 1–8.

6 Numerical simulations

In this section, we illustrate the results of Theorems 1–8 by performing numerical simulations. Moreover, we study the effect of HTLV-I infection on the HIV mono-infected individuals by making a comparison between the dynamics of HIV monoinfection and HIV/HTLV-I co-infection. Otherwise, we investigate the influence of HIV infection on the HTLV-I mono-infected individuals by conducting a comparison between the dynamics of HTLV-I mono-infection and HIV/HTLV-I co-infection.
For solving system (3) numerically we fix the values of some parameters taken from literature as mentioned in Table 4. To verify the stability of the eight equilibria given in Theorems 1–8, we vary some parameters that affect the values of the threshold parameters which in turn control the existence and stability of the equilibria. We confirm that we have assumed some values of the model’s parameters just to conduct the numerical simulations. In fact, it is challenging to collect real data from HIV/HTLV-I co-infected patients. However, if one has real data then the model’s parameters can be estimated and the validity of the model can be established.

### 6.1 Stability of the equilibria

In this subsection, we illustrate our global stability results given in Theorems 1–8. To do so, we show that the solution of the system starting from any initial point (at any disease stage) in the feasible set \( \Theta \) will converge to only one of the eight equilibria of the system. Therefore, we choose three different initial conditions for the system (3) as follows:

**Initial-1:**

\[
(S(0), L(0), I(0), E(0), Y(0), V(0), C^I(0), C^Y(0)) = (600, 1.5, 1.5, 30, 0.3, 5, 1, 3),
\]

**Initial-2:**

\[
(S(0), L(0), I(0), E(0), Y(0), V(0), C^I(0), C^Y(0)) = (500, 1, 1, 20, 0.2, 2, 2, 2),
\]

**Initial-3:**

\[
(S(0), L(0), I(0), E(0), Y(0), V(0), C^I(0), C^Y(0)) = (300, 0.5, 0.5, 10, 0.1, 1.5, 3, 1).
\]

Choosing selected values of \( \eta_1, \eta_2, \sigma_1 \) and \( \sigma_2 \) under the above initial conditions leads to the following scenarios:

**Scenario 1 (Stability of \( D_0 \)):** \( \eta_1 = 0.0001, \eta_2 = 0.001 \) and \( \sigma_1 = \sigma_2 = 0.2 \). For this set of parameters, we have \( R_1 = 0.49 < 1 \) and \( R_2 = 0.23 < 1 \). Figure 2 displays that the trajectories initiating with Initial-1, Initial-2 and Initial-3 reach the

| Equilibrium point \( D_0 \) | Global stability conditions |
|-----------------------------|----------------------------|
| \( (S_0, 0, 0, 0, 0, 0, 0, 0) \) | \( R_1 \leq 1 \) and \( R_2 \leq 1 \) |
| \( (S_1, L_1, I_1, 0, 0, V_1, 0, 0) \) | \( R_1 > 1, R_2/ R_1 \leq 1 \) and \( R_3 \leq 1 \) |
| \( (S_2, 0, 0, E_2, Y_2, 0, 0, 0) \) | \( R_2 > 1, R_1/ R_2 \leq 1 \) and \( R_4 \leq 1 \) |
| \( (S_3, L_3, I_3, 0, 0, V_3, C^I_1, 0) \) | \( R_3 > 1 \) and \( R_5 \leq 1 \) |
| \( (S_4, 0, 0, E_4, Y_4, 0, 0, C^I_1) \) | \( R_4 > 1 \) and \( R_6 \leq 1 \) |
| \( (S_5, L_4, I_4, E_4, Y_5, 0, V_5, C^I_1) \) | \( R_5 > 1, R_6 \leq 1 \) and \( R_1/ R_2 > 1 \) |
| \( (S_6, L_4, I_4, E_5, Y_6, 0, V_6, 0, C^I_2) \) | \( R_6 > 1, R_7 \leq 1 \) and \( R_2/ R_1 > 1 \) |
| \( (S_7, L_5, I_5, E_7, Y_7, 0, V_7, C^I_1, C^I_2) \) | \( R_7 > 1 \) and \( R_8 > 1 \) |
equilibrium $\mathcal{D}_0 = (1000, 0, 0, 0, 0, 0, 0, 0)$. This shows that $\mathcal{D}_0$ is G.A.S according to Theorem 1. In this situation both HIV and HTLV-I will be died out.

**Scenario 2 (Stability of $\mathcal{D}_1$):** $\eta_1 = \eta_2 = 0.0005, \sigma_1 = 0.003$ and $\sigma_2 = 0.2$. With such choice we get $\mathcal{R}_3 = 0.12 < 1 < 2.43 = \mathcal{R}_1, \mathcal{R}_3 = 0.47 < 1$ and hence $\mathcal{R}_2/\mathcal{R}_1 = 0.05 < 1$. Therefore, the conditions in Table 2 are verified. In fact, the equilibrium point $\mathcal{D}_1 = (411.22, 8.03, 11.45, 0, 0, 28.64, 0, 0)$. Figure 3 displays that the trajectories initiating with Initial-1, Initial-2 and Initial-3 tend to $\mathcal{D}_1$. Therefore, the numerical results support Theorem 2. This case corresponds to a chronic HIV mono-infection but with unstimulated CTL-mediated immune response.

**Scenario 3 (Stability of $\mathcal{D}_2$):** $\eta_1 = 0.0001, \eta_2 = 0.01, \sigma_1 = 0.001$ and $\sigma_2 = 0.05$. Then, we calculate $\mathcal{R}_1 = 0.49 < 1 < 2.33 = \mathcal{R}_2, \mathcal{R}_4 = 0.78 < 1$ and then $\mathcal{R}_1/\mathcal{R}_2 = 0.21 < 1$. Hence, the conditions in Table 2 are satisfied. The numerical results show that $\mathcal{D}_2 = (421.67, 0, 0, 89.2, 1.37, 0, 0, 0)$ exists. Figure 4 illustrates that the trajectories initiating with Initial-1, Initial-2 and Initial-3 tend to $\mathcal{D}_2$. Thus, the numerical results consistent with Theorem 3. This situation leads to a persistent HTLV-I mono-infection with unstimulated CTL-mediated immune response.

**Scenario 4 (Stability of $\mathcal{D}_3$):** $\eta_1 = 0.001, \eta_2 = 0.005$ and $\sigma_1 = \sigma_2 = 0.01$. Then, we calculate $\mathcal{R}_3 = 1.39 > 1$ and $\mathcal{R}_5 = 0.33 < 1$. Table 2 and Fig. 5 show that the trajectories initiating with Initial-1, Initial-2 and Initial-3 tend to $\mathcal{D}_3 = (285.71, 9.74, 10, 0, 0, 25, 0.97, 0)$. Therefore, $\mathcal{D}_3$ is G.A.S and this agrees with Theorem 4. Hence, a chronic HIV mono-infection with HIV-specific CTL-mediated immune response is attained.

**Scenario 5 (Stability of $\mathcal{D}_4$):** $\eta_1 = 0.0007, \eta_2 = 0.1, \sigma_1 = 0.05$ and $\sigma_2 = 0.3$. Then, we calculate $\mathcal{R}_4 = 5.37 > 1$ and $\mathcal{R}_6 = 0.79 < 1$. According to Table 2, $\mathcal{D}_4$ exists with $\mathcal{D}_4 = (230.77, 0, 0, 118.4, 0.33, 0, 0, 4.35)$. In Fig. 6, we show that the trajectories initiating with Initial-1, Initial-2 and Initial-3 tend to $\mathcal{D}_4$ and then it is G.A.S which agrees with Theorem 5. Hence, a chronic HTLV-I mono-infection with HTLV-specific CTL-mediated immune response is attained.
Scenario 6 (Stability of $\mathcal{R}_5$):

$\eta_1 = 0.001, \quad \eta_2 = 0.01, \quad \sigma_1 = 0.05 \quad \text{and} \quad \sigma_2 = 0.08$. Then, we calculate $\mathcal{R}_5 = 1.55 > 1$, $\mathcal{R}_8 = 0.85 < 1$ and $\mathcal{R}_1/\mathcal{R}_2 = 2.09 > 1$. Table 2 and the numerical results demonstrated in Fig. 7.
show that $D_5 = (421.67, 2.88, 2, 56.68, 0.87, 5, 2.63, 0)$ exists and it is G.A.S and this agrees with Theorem 6. As a result, a chronic co-infection with HIV and HTLV-I is attained where the HIV-specific CTL-mediated immune
response is active and the HTLV-specific CTL-mediated immune response is unstimulated.

**Scenario 7 (Stability of $R_6 > 1$, $R_7 < 1$ and $R_2 < 1$)**: We compute $R_6 = 1.62 > 1$, $R_7 = 0.88 < 1$ and $R_2/R_1 = 3.19 > 1$. Based on the

![Graphs showing](https://via.placeholder.com/150)
conditions in Table 2, the equilibrium $D_6 = (342.68, 5.23, 7.45, 42.21, 0.2, 18.64, 0.219)$ exists. Moreover, the numerical results plotted in Fig. 8 show that $D_6$ is G.A.S and this illustrates Theorem 7. As a result, a chronic co-infection with HIV and HTLV-I is attained where the HTLV-specific CTL-mediated immune

Fig. 5 The behavior of solution trajectories of system (3) when $R_3 > 1$ and $R_5 \leq 1$
response is active and the HIV-specific CTL-mediated immune response is unstimulated.

**Scenario 8 (Stability of $\mathcal{R}_7 ^ {\mathbb{C}_2}$):** $\eta_1 = 0.0006$, $\eta_2 = 0.04$, $\sigma_1 = 0.05$ and $\sigma_2 = 0.5$. These data give $\mathcal{R}_7 = 1.39 > 1$ and $\mathcal{R}_8 = 4.43 > 1$. According to Table 2, the
equilibrium $D_7$ exists. Figure 9 illustrates that the trajectories initiating with Initial-1, Initial-2 and Initial-3 tend to $D_7 = (476.19, 1.95, 2, 58.64, 0.2, 5, 0.97, 3.42)$. The numerical results displayed in Fig. 9 show that $D_7$ is G.A.S based on Theorem 8. In this case, a chronic co-infection with HIV and HTLV-I is attained where both HIV-
specific CTL-mediated and HTLV-specific CTL-mediated immune responses are working.

To further confirmation, we calculate the Jacobian matrix \( J = J(S, L, I, E, Y, V, C^I, C^Y) \) of system (3) as in the following form:

\[
J = \begin{pmatrix}
-(x + \eta_1V + \eta_2Y) & 0 & 0 & 0 & -\eta_2S & -\eta_1S & 0 & 0 \\
(1 - \beta)\eta_1V & -(\gamma + \lambda) & 0 & 0 & 0 & (1 - \beta)\eta_1S & 0 & 0 \\
\beta_1V & \lambda & -(a + \mu_1C^I) & 0 & 0 & \beta_1S & -\mu_1I & 0 \\
\phi_1Y & 0 & 0 & -(\psi + \omega) & \phi_2S + \kappa r^* & 0 & 0 & 0 \\
0 & 0 & 0 & \psi & (1 - \kappa)r^* - (\delta + \mu_2C^Y) & 0 & 0 & -\mu_2Y \\
0 & 0 & b & 0 & 0 & -\varepsilon & 0 & 0 \\
0 & 0 & \sigma_1C^I & 0 & 0 & 0 & \sigma_1I - \pi_1 & 0 \\
0 & 0 & 0 & \sigma_2C^Y & 0 & 0 & \sigma_2 - \pi_2 & \\
\end{pmatrix}
\]

Then, we calculate the eigenvalues \( \lambda_i, i = 1, 2, \ldots, 8 \) of the matrix \( J \) at each equilibrium. The examined steady will be locally stable if all its eigenvalues satisfy the following condition:

\[
\text{Re}(\lambda_i) < 0, \ i = 1, 2, \ldots, 8.
\]

We use the parameters \( \eta_1, \eta_2, \sigma_1 \) and \( \sigma_2 \) the same as given above to compute all positive equilibria and the corresponding eigenvalues. From the scenarios 1-8, we present in Table 5 the positive equilibria, the real parts of the eigenvalues and whether the equilibrium is locally stable or unstable. The numerical results are consistent with the global stability results. For each of the above mentioned scenarios, only one equilibrium is asymptotically stable, while the others are unstable.

### 6.2 Comparison results

In this subsection, we study the influence of HTLV-I infection on HIV mono-infection dynamics, and how affect the HIV infection on the dynamics of HTLV-I mono-infection as well.

**Impact of HTLV-I infection on HIV mono-infection dynamics**

To investigate the effect of HTLV-I infection on HIV mono-infection dynamics, we make a comparison between model (3) and the following HIV mono-infection model:

\[
\begin{aligned}
\dot{S} &= \rho - \alpha S - \eta_1SV, \\
\dot{L} &= (1 - \beta)\eta_1SV - (\lambda + \gamma)L, \\
\dot{I} &= \beta_1SV + \lambda L - aI - \mu_1C^I, \\
\dot{V} &= bI - \varepsilon V, \\
C^I &= \sigma_1C^I - \pi_1C^I.
\end{aligned}
\]  

We fix parameters \( \eta_1 = 0.0006 \), \( \sigma_1 = 0.05 \), and \( \sigma_2 = 0.5 \) and consider the following initial condition:

**Initial-4:** \( (S(0), L(0), I(0), E(0), Y(0), V(0), C^I(0), C^Y(0)) = (600, 2.4, 1.8, 60, 0.2, 4.5, 1.8, 3.5) \).
We choose two values of the parameter $\eta_2$ as $\eta_2 = 0.04$ (HIV/HTLV-I co-infection), and $\eta_2 = 0.0$ (HIV mono-infection). It can be seen from Fig. 10 that when the HIV mono-infected individual is co-infected with HTLV-I then the concentrations of susceptible CD4$^+$ T cells, silent HIV-infected cells and HIV-

Fig. 8 The behavior of solution trajectories of system (3) when $R_6 > 1$, $R_7 \leq 1$ and $R_2/R_1 > 1$
specific CTLs are decreased. Although, the concentration of free HIV particles tend to the same value in both HIV mono-infection and HIV/HTLV-I co-infection. Indeed, such observation is compatible with the study that has been performed by Vandormael et al. in 2017 [61]. The researchers have not found any worthy
differences in the concentration of HIV virus particles in comparison between HIV mono-infected and HIV/HTLV-I co-infected patients.

**Impact of HIV infection on HTLV-I mono-infection dynamics**

To investigate the effect of HIV infection on HTLV-I mono-infection dynamics, we make a comparison between model \((3)\) and the following HTLV-I mono-infection model:

\[
\begin{align*}
\dot{S} &= \rho - aS - \eta_2 SY, \\
\dot{E} &= \phi\eta_2 SY + \kappa r^* Y - (\psi + \omega)E, \\
\dot{Y} &= \psi E - (1 - \kappa) r^* Y - \delta^* Y - \mu_2 C^Y Y, \\
\dot{C}^Y &= \sigma_2 C^Y Y - \pi_2 C^Y.
\end{align*}
\]

We fix parameters \(\eta_2 = 0.01; \sigma_1 = 0.05, \text{and } \sigma_2 = 0.5\) and consider the following initial condition:

**Initial-5:** \((S(0), L(0), I(0), E(0), Y(0), V(0), C^Y(0), C^V(0)) = (700, 4, 2, 21, 0.198, 5, 4.5, 0.6)\).

We choose two values of the parameter \(\eta_1\) as \(\eta_1 = 0.001\) (HIV/HTLV-I co-infection), and \(\eta_1 = 0.0\) (HTLV-I mono-infection). It can be seen from Fig. 11 that when the HTLV-I mono-infected individual is co-infected with HIV then the concentrations of susceptible CD4\(^{+}\) T cells, silent HTLV-infected cells and HTLV-specific CTLs are decreased. Although, the concentration of Tax-expressing HTLV-infected cells tend to the same value in both HTLV-I mono-infection and HIV/HTLV-I co-infection.

**7 Conclusion and discussions**

This paper investigates the global behavior of solutions of system that was used to study HIV/HTLV-I co-infection dynamics. We incorporated the effect of HIV-specific CTLs and HTLV-specific CTLs into the model. The HIV can be transmitted to the susceptible CD4\(^{+}\) T cells by virus-to-cell transmission, while HTLV-I has two modes of transmission, (i) horizontal transmission via direct cell-to-cell contact, and (ii) vertical transmission through mitotic division of Tax-expressing HTLV-infected cells. We studied the basic properties of the model by showing that the solutions are nonnegative and bounded. We derived eight threshold parameters that governed the existence and stability of the eight equilibria of the model. We constructed suitable Lyapunov functions and utilized Lyapunov–LaSalle asymptotic stability theorem to establish the global asymptotic stability of all equilibria. We conducted numerical simulations to support and clarify our theoretical results. We studied the effect of HIV infection on HTLV-I mono-infection dynamics and vice versa. The model analysis suggested that co-infected individuals with both viruses will have smaller number of healthy CD4\(^{+}\) T cells in comparison with HIV or HTLV-I mono-infected individuals. It was reported in [62] that no treatments exist for acute or chronic HTLV-I infection. However, antiviral treatments of HIV infection is currently used to suppress viral replication. For example, reverse transcriptase inhibitors (RTIs) can prevent the establishment of productive infection of a cell. Model \((4)\) under the effect of RTIs can be written as:
### Table 5: Local stability of positive equilibria, $D_i = 0.1, 0.7, 1, ...$.

| Scenario | The equilibria | Stability |
|----------|----------------|-----------|
| 1        | $D_0 = (1000, 0, 0, 0, 0, 0, 0)$ | Stable |
|          | $D_0 = (1000, 0, 0, 0, 0, 0, 0)$ | Stable |
| 2        | $D_0 = (1000, 0, 0, 0, 0, 0, 0)$ | Stable |
|          | $D_0 = (1000, 0, 0, 0, 0, 0, 0)$ | Stable |
| 3        | $D_0 = (1000, 0, 0, 0, 0, 0, 0)$ | Stable |
| 4        | $D_0 = (1000, 0, 0, 0, 0, 0, 0)$ | Stable |
| 5        | $D_0 = (1000, 0, 0, 0, 0, 0, 0)$ | Stable |
| 6        | $D_0 = (1000, 0, 0, 0, 0, 0, 0)$ | Stable |
| 7        | $D_0 = (1000, 0, 0, 0, 0, 0, 0)$ | Stable |
Table 5 continued

| Scenario | The equilibria | \((\text{Re}(\lambda_i), i = 1, 2, ..., 8)\) | Stability |
|----------|----------------|--------------------------------------|-----------|
| 8        | \(D_0 = (1000, 0, 0, 0, 0, 0, 0, 0)\) | \((-2.86, 0.46, -0.32, -0.28, -0.1, -0.1, 0.08, -0.01)\) | Unstable |
|          | \(D_1 = (342.68, 8.96, 12.79, 0, 0, 0, 0, 0)\) | \((-2.37, 0.54, -0.35, -0.23, -0.1, -0.01, -0.01, 0.02)\) | Unstable |
|          | \(D_2 = (105.42, 0, 0, 137.97, 2.12, 0, 0, 0)\) | \((-2.13, 0.96, -0.42, -0.22, -0.17, -0.1, -0.07, -0.01)\) | Unstable |
|          | \(D_3 = (769.23, 3.15, 2.0, 0, 0, 5.3, 11.0)\) | \((-2.88, -0.41, -0.27, -0.03, -0.03, -0.1, 0.06, -0.01)\) | Unstable |
|          | \(D_4 = (555.56, 0, 0, 68.41, 0.2, 0, 0, 4.16)\) | \((-2.55, -0.95, -0.33, 0.16, -0.1, -0.07, -0.03, -0.01)\) | Unstable |
|          | \(D_6 = (342.68, 5.23, 7.45, 42.21, 0.2, 18.64, 0, 2.19)\) | \((-2.37, -0.57, -0.35, 0.27, -0.06, -0.02, -0.02, -0.02)\) | Unstable |
|          | \(D_7 = (476.19, 1.95, 2.58, 64.0, 0.2, 5, 0.97, 3.42)\) | \((-2.52, -0.81, -0.37, -0.01, -0.01, -0.06, -0.03, -0.01)\) | Stable |
Fig. 10 The influence of HTLV-I infection rate ($\eta_2 \neq 0$) on HIV mono-infection dynamics (22) will cause a chronic HIV/HTLV-I co-infection.
Fig. 11  The influence of HIV infection rate ($\eta_1 \neq 0$) on HTLV mono-infection dynamics (23) will cause a chronic HIV/HTLV-I co-infection.
Therefore to clear the HIV from the body by RTIs we have three cases:

1. **\( R_1 \leq 1 \) and **\( R_2 \leq 1 \): Let \( \ell \) be chosen such that

\[
\frac{(1 - \ell)\eta_1 b S_0 (\beta \gamma + \lambda)}{a e (\gamma + \lambda)} \leq 1,
\]

\[
\ell \geq \ell_1^{\text{min}} = \max \left\{ 0, 1 - \frac{a e (\gamma + \lambda)}{\eta_1 b S_0 (\beta \gamma + \lambda)} \right\}.
\]

It follows that when \( \ell \geq \ell_1^{\text{min}} \) and \( R_2 \leq 1 \), the system will converge to \( D_0 \) where both HIV and HTLV-I will be cleared from the body.

2. **\( R_2 > 1 \), **\( R_4 \leq 1 \) and **\( R_1/R_2 \leq 1 \): Let \( \ell \) be chosen such that

\[
\frac{(1 - \ell)\eta_1 b S_0 (\beta \gamma + \lambda)}{a e \varphi_2 \psi (\gamma + \lambda)} \leq 1,
\]

\[
\Rightarrow \ell \geq \ell_2^{\text{min}} = \max \left\{ 0, 1 - \frac{a e \varphi_2 \psi (\gamma + \lambda)}{\eta_1 b (\beta \gamma + \lambda) [(\delta - r) \psi + \delta \omega]} \right\}.
\]

Thus, if \( R_2 > 1 \), \( R_4 \leq 1 \) and \( \ell \geq \ell_2^{\text{min}} \), then the system will converge to \( D_2 \) where the HIV is cleared while the HTLV-I will be chronic with inactive HTLV-specific CTL immune response.

3. **\( R_4 > 1 \) and **\( R_6 \leq 1 \): Let \( \ell \) is chosen such that \( R_6 \leq 1 \) as:
\[
\mathcal{R}_6 = \frac{(1 - \ell_0)\rho b \eta_1 \sigma_2 (\beta \gamma + \lambda)}{a c (\gamma + \lambda) (\pi_2 \eta_2 + x \sigma_2)} \leq 1,
\]

\[
\implies \ell \geq \ell_3^\text{min} = \max \left\{ 0, 1 - \frac{a c (\gamma + \lambda) (\pi_2 \eta_2 + x \sigma_2)}{\rho b \eta_1 \sigma_2 (\beta \gamma + \lambda)} \right\}.
\]

Therefore, if \( \mathcal{R}_4 > 1 \) and \( \ell \geq \ell_3^\text{min} \), then the system will converge to \( \mathcal{D}_4 \) where the HIV is cleared while the HTLV-I will be chronic with active HTLV-specific CTL immune response.

References

1. WHO: Global Health Observatory (GHO) data. HIV/AIDS. http://www.who.int/gho/hiv/en/ (2018).
2. Nowak, M.A., Bangham, C.R.M.: Population dynamics of immune responses to persistent viruses. Science 272(5258), 74–79 (1996)
3. Hernandez-Vargas, E.A.: Modeling kick-kill strategies toward HIV cure. Front. Immunol. 8, Article ID: 995 (2017)
4. Pedro, K.D., Henderson, A.J., Agosto, L.M.: Mechanisms of HIV-1 cell-to-cell transmission and the establishment of the latent reservoir. Virus Res. 265, 115–121 (2019)
5. Rong, L., Perelson, A.S.: Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy, Journal of Theoretical Biology. PLoS Comput. Biol. 5(10), e1000533 (2009)
6. Perelson, A.S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saxkela, K., Markowitz, M., Ho, D.D.: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387(6629), 188–191 (1997)
7. Perelson, A.S., Nelson, P.W.: Mathematical analysis of HIV-1 dynamics in vivo. SIAM Rev. 41(3), 3–44 (1999)
8. Callaway, D.S., Perelson, A.S.: HIV-1 infection and low steady state viral loads. Bull. Math. Biol. 64(1), 29–64 (2002)
9. Elaiw, A.M., Azoz, S.A.: Global properties of a class of HIV infection models with Beddington–DeAngelis functional response. Math. Methods Appl. Sci. 36(4), 383–394 (2013)
10. Elaiw, A.M., Alshamrani, N.H.: Stability of a general CTL-mediated immunity HIV infection model with silent infected cell-to-cell spread. Adv. Differ. Equ. 2020, 355 (2020)
11. Elaiw, A.M., Elnahary, E.K., Raezah, A.A.: Effect of cellular reservoirs and delays on the global dynamics of HIV. Adv. Differ. Equ. 2018(1), Article Number: 85 (2018)
12. Liu, H., Zhang, J.-F.: Dynamics of two time delays differential equation model to HIV latent infection. Phys. A 514(C), 384–395 (2019)
13. Lairmore, M.D., Haines, R., Anupam, R.: Mechanisms of human T lymphotropic virus type I transmission and disease. Curr. Opin. Virol. 2(4), 474–481 (2012)
14. Lim, A.G., Maini, P.K.: HTLV-I infection: a dynamic struggle between viral persistence and host immunity. J. Theor. Biol. 352, 92–108 (2014)
15. Pan, X., Chen, Y., Shu, H.: Rich dynamics in a delayed HTLV-I infection model: stability switch, multiple stable cycles, and torus. J. Math. Anal. Appl. 479(2), 2214–2235 (2019)
16. Asquith, B., Bangham, C.R.M.: The dynamics of T-cell fratricide: application of a robust approach to mathematical modeling in immunology. J. Theor. Biol. 222(1), 53–69 (2003)
17. Tokudome, S., et al.: Incidence of adult T cell leukemia/lymphoma among human T lymphotropic virus type I carriers in Saga, Japan. Cancer Res. 49(1), 226–228 (1989)
18. Stilianakis, N.I., Seydel, J.: Modeling the T-cell dynamics and pathogenesis of HTLV-I infection. Bull. Math. Biol. 61(5), 935–947 (1999)
19. Vargas-De-Leon, C.: The complete classification for global dynamics of a model for the persistence of HTLV-I infection. Appl. Math. Comput. 237(15), 489–493 (2014)
20. Wang, L., Li, M.Y., Kirschner, D.: Mathematical analysis of the global dynamics of a model for HTLV-I infection and ATL progression. Math. Biosci. 179(2), 207–217 (2002)

Birkhäuser
22. Yamamoto, N., Okada, M., Koyanagi, Y., Kannagi, M., Hinuma, Y.: Transformation of human leukocytes by cocultivation with an adult T cell leukemia virus producer cell line. Science 217(4561), 737–739 (1982)
23. Bangham, C.R.M.: The immune response to HTLV-I. Curr. Opin. Immunol. 12(4), 397–402 (2000)
24. Li, M.Y., Lim, A.G.: Modelling the role of Tax expression in HTLV-I persistence in vivo. Bull. Math. Biol. 73(12), 3008–3029 (2011)
25. Asquith, B., Bangham, C.R.M.: Quantifying HTLV-I dynamics. Immunol. Cell Biol. 85(4), 280–286 (2007)
26. Rosenberg, E.S., Altfeld, M., Poon, S.H., et al.: Immune control of HIV-1 following early treatment of acute infection. Nature 407(6803), 523–526 (2000)
27. Shu, H., Wang, L., Watmough, J.: Global stability of a nonlinear viral infection model with infinitely distributed intracellular delays and CTL immune responses. SIAM J. Appl. Math. 73(3), 1280–1302 (2013)
28. Guo, T., Qiu, Z.: The effects of CTL immune response on HIV infection model with potent therapy, latently infected cells and cell-to-cell viral transmission. Math. Biosci. Eng. 16(6), 6822–6841 (2019)
29. Elaiw, A.M., AlShamrani, N.H.: Global stability of a delayed adaptive immunity viral infection with two routes of infection and multi-stages of infected cells. Commun. Nonlinear Sci. Numer. Simul. 86, Article ID 105259 (2020)
30. Bangham, C.R.M.: CTL quality and the control of human retroviral infections. Eur. J. Immunol. 39(7), 1700–1712 (2009)
31. Gomez-Acevedo, H., Li, M.Y., Jacobson, S.: Multi-stability in a model for CTL response to HTLV-I infection and its consequences in HAM/TSP development, and prevention. Bull. Math. Biol. 72(3), 681–696 (2010)
32. Li, M.Y., Shu, H.: Multiple stable periodic oscillations in a mathematical model of CTL response to HTLV-I infection. Bull. Math. Biol. 73(8), 1774–1793 (2011)
33. Wang, L., Liu, Z., Li, Y., Xu, D.: Complete dynamical analysis for a nonlinear HTLV-I infection model with distributed delay. CTL response and immune impairment. Discr. Contin. Dyn. Syst. 25(3), 917–933 (2020)
34. Wang, Y., Ma, W.: Dynamics analysis of an HTLV-I infection model with mitotic division of actively infected cells and delayed CTL immune response. Math. Methods Appl. Sci. 41(8), 3000–3017 (2018)
35. Li, S., Zhou, Y.: Backward bifurcation of an HTLV-I model with immune response. Discr. Contin. Dyn. Syst. Ser. B 21(3), 863–881 (2016)
36. Wang, W., Ma, W.: Global dynamics of a reaction and diffusion model for an HTLV-I infection with mitotic division of actively infected cells. J. Appl. Anal. Comput. 7(3), 899–930 (2017)
37. Pilotti, E., Bianchi, M.V., De Maria, A., Bozzano, F., Romanelli, M.G., Bertazzoni, U., Casoli, C.: HTLV-1/-2 and HIV-1 co-infections: retroviral interference on host immune status. Front. Microbiol. 4, Article ID 372 (2013)
38. Beilke, M.A., Theall, K.P., O’Brien, M., Clayton, J.L., Benjamin, S.M., Winsor, E.L., Kissinger, P.J.: Clinical outcomes and disease progression among patients coinfected with HIV and human T lymphotropic virus types 1 and 2. Clin. Infect. Dis. 39(2), 256–263 (2004)
39. Isache, C., Sands, M., Guzman, N., Figueroa, D.: HTLV-I and HIV-1 co-infection: a case report and review of the literature. IDCases 4, 53–55 (2016)
40. Tiulius Silva, M., de Melo Espindola, O., Bezerra Leite, A.C., Araújo, A.: Neurological aspects of HIV/human T lymphotropic virus coinfection. AIDS Rev. 11(2), 71–78 (2009)
41. Rockwood, N., Cook, L., Kagdi, H., Basnayake, S., Bangham, C.R.M., Pozniak, A.L., Taylor, G.P.: Immune compromise in HIV-1/HTLV-1 coinfection with paradoxical resolution of CD4 lymphocytosis during antiretroviral therapy: A case report. Medicine 94(50), e2275 (2015)
42. Brites, C., Sampalo, J., Oliveira, A.: HIV/human T-cell lymphotropic virus coinfection revisited: impact on AIDS progression. AIDS Rev. 11(1), 8–16 (2009)
43. Ticona, E., Huaman, M.A., Yunque, O., Zunt, J.R.: HIV and HTLV-1 coinfection: the need to initiate antiretroviral therapy. J. Int. Assoc. Providers AIDS Care 12(6), 373–374 (2013)
44. Geddes, V.E.V., José, D.P., Leal, F.E., Nixond, D.F., Tanuri, A., Aquiag, R.S.: HTLV-I Tax activates HIV-1 transcription in latency models. Virology 504, 45–51 (2017)
45. Bellomo, N., Painter, K.J., Tao, Y., Winkler, M.: Occurrence vs. absence of taxis-driven instabilities in a May–Nowak model for virus infection. SIAM J. Appl. Math. 79(5), 1990–2010 (2019)
47. Elaiw, A.M., AlAgha, A.D.: Global analysis of a reaction–diffusion within-host malaria infection model with adaptive immune response. Mathematics 8, 563 (2020)
48. Nelson, P.W., Murray, J.D., Perelson, A.S.: A model of HIV-1 pathogenesis that includes an intracellular delay. Math. Biosci. 163(2), 201–215 (2000)
49. Elaiw, A.M., Raezah, A.A.: Stability of general virus dynamics models with both cellular and viral infections and delays. Math. Methods Appl. Sci. 40(16), 5863–5880 (2017)
50. Elaiw, A.M., Almualllem, N.A.: Global dynamics of delay-distributed HIV infection models with differential drug efficacy in cocirculating target cells. Math. Methods Appl. Sci. 39(1), 4–31 (2016)
51. Elaiw, A.M., Alshehaiween, S.F.: Global stability of delay-distributed viral infection model with two modes of viral transmission and B-cell impairment. Math. Methods Appl. Sci. 43(11), 6677–6701 (2020)
52. Culshaw, R.V., Ruan, S.: A delay-differential equation model of HIV infection of CD4+ T-cells. Math. Biosci. 165(1), 27–39 (2000)
53. Gibelli, L., Elaiw, A., Alghamdi, M.A., Althiabi, A.M.: Heterogeneous population dynamics of active particles: progression, mutations, and selection dynamics. Math. Methods Appl. Sci. 27(4), 617–640 (2017)
54. Barbashin, E.A.: Introduction to the Theory of Stability. Wolters-Noordhoff, Groningen (1970)
55. LaSalle, J.P.: The Stability of Dynamical Systems. SIAM, Philadelphia (1976)
56. Lyapunov, A.M.: The General Problem of the Stability of Motion. Taylor & Francis Ltd, London (1992)
57. Perelson, A.S., Kirschner, D.E., de boer, R.: Dynamics of HIV infection of CD4+ T cells. Math. Biosci. 114, 81–125 (1993)
58. Mohri, H., Bonhoeffer, S., Monard, S., Perelson, A.S., Ho, D.D.: Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science 279, 1223–1227 (1998)
59. Wodarz, D.: Mathematical models of immune effector responses to viral infections: virus control versus the development of pathology. J. Comput. Appl. Math. 184(1), 301–319 (2005)
60. Sahani, S.K., Yashi: Effects of eclipse phase and delay on the dynamics of HIV infection. J. Biol. Syst. 26(3), 421–454 (2018)
61. Vandormael, A., Rego, F., Danaviah, S., Carlos Junior Alcantara, L., Boulware, D.R., de Oliveira, T.: CD4+ T-cell count may not be a useful strategy to monitor antiretroviral therapy response in HTLV-I/HIV co-infected patients. Curr. HIV Res. 15(3), 225–231 (2017)
62. Barski, M.S., Minnell, J.J., Maertens, G.N.: Inhibition of HTLV-1 infection by HIV-1 first- and second-generation integrase strand transfer inhibitors. Front. Microbiol. 10, Article ID: 1877 (2019)

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

A. M. Elaiw1,2  N. H. AlShamrani1,3

A. M. Elaiw
a_m_elaiw@yahoo.com

N. H. AlShamrani
nhalshamrani@uj.edu.sa

1 Department of Mathematics, Faculty of Science, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia
2 Department of Mathematics, Faculty of Science, Al-Azhar University, Assiut Branch, Assiut, Egypt
3 Department of Mathematics, Faculty of Science, University of Jeddah, P.O. Box 80327, Jeddah 21589, Saudi Arabia